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1. Abstract 
 
As conventional anti-cancer regimens like radiation or chemotherapy often fail to cure human 
cancers new treatment strategies are required. The application of replication-competent 
viruses as anti-tumor agents – termed virotherapy – represents a novel and promising 
approach to selectively eradicate cancerous cells while concomitantly sparing normal tissue 
from destruction. Thereby the therapeutic vector propagated and infected cells are lysed. To 
restrict viral replication to tumor tissue it is important to understand the molecular 
mechanisms that govern cancer development, and the interactions of therapeutic viruses with 
their target cells. This thesis was aimed to explore the interaction between two different 
therapeutic viral agents – a conditionally replicating Adenovirus (crAd) and the natural tumor 
virus Vesicular Stomatitis Virus (VSV) – and human cancer cells.  
First, the altering transcriptional status of p53 in normal and transformed cells was utilized for 
the regulation of adenoviral replication applying a novel regulation mechanism that leads to 
the destruction of the vector genome in normal tissue. This mechanism is based on the p53-
dependent expression of the rare-cutting DNA endonuclease I-Sce I from yeast. In cells with 
active p53, I-Sce-I specifically cleaves the viral backbone as determined by PCR. 
Consequently, replication of I-Sce I-encoding viruses is impaired in contrast to EGFP-
expressing control vectors in p53-positive cell, whereas no difference in cells with non-
functional p53 could be observed. Furthermore, this concept can be combined with an 
additional transcriptional repressor Gal4-KRAB. In summary, tightly regulated, conditionally 
replicating adenoviruses have been established that combine transcriptional regulation as well 
as vector destruction mechanisms for improved safety and efficacy of virotherapeutic 
treatment of solid tumors. 
Second, the molecular mechanisms involved in VSV-induced apoptosis were investigated 
focusing on proteins of the B-cell lymphoma 2 (Bcl-2)-family. VSV was demonstrated to 
rapidly decrease myeloid cell leukemia 1 (Mcl-1) protein levels. Mcl-1 elimination depends 
on the combination of VSV-mediated block of cellular protein biosynthesis and continued 
proteasome-dependent degradation of Mcl-1. Rescue of Mcl-1 inhibited apoptosis confirming 
that Mcl-1 down-regulation contributes to VSV-induced apoptosis. In vitro and in vivo, VSV 
virotherapy in combination with chemotherapy revealed an enhanced therapeutic effect 
compared to single treatments. In summary, these data suggest that Mcl-1 is a key component 
of intracellular defense mechanisms against VSV infection. Additionally, strong evidence is 
provided that this anti-viral mechanism can be successfully exploited by oncolytic VSV to 
enhance anti-tumor therapy in combination with conventional chemotherapy in vitro and in 
vivo. 
 
Keywords: oncolytic virus, apoptosis, Mcl-1 
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2. Zusammenfassung 
 
Konventionelle Tumorbehandlungen wie Strahlen- oder Chemotherapie führen oftmals nicht 
zum Heilungserfolg, weshalb neuartige Therapieansätze nötig sind. Der Einsatz von 
replikativen Viren als therapeutische Agentien – bezeichnet als Virotherapie – stellt einen 
vielversprechenden und innovativen Ansatz zur selektiven Zerstörung von Krebszellen dar. 
Dabei wird ausgenutzt, dass virale Vektoren infizierte Zellen lysieren und es gleichzeitig zur 
Amplifikation der therapeutischen Viren kommt. Um die virale Replikation auf Tumorzellen 
zu beschränken, ist es von großer Bedeutung die molekularen Mechanismen der 
Krebsentwicklung und der Virus-Wirtsinteraktion zu verstehen. In dieser Arbeit wurden daher 
die Interaktionen zwischen therapeutisch relevanten Viren – einem konditionell-
replizierenden Adenovirus und dem natürlichen Tumorvirus Vesikuläres Stomatitis Virus 
(VSV) – und menschlichen Krebszelllinien analysiert. 
Der unterschiedliche transkriptionelle Status von p53 in normalen und transformierten Zellen 
wurde ausgenutzt, um die Replikation eines adenoviralen Vektors durch einen neuartigen, auf 
der Hefe-DNA-Endonuklease I-Sce I basierenden Regulationsmechanismus auf Krebszellen 
zu begrenzen. Virus-kodiertes I-Sce I wurde p53-abhängig exprimiert und spaltete in p53-
positiven Zellen das adenovirale Genom an bestimmten Stellen hochspezifisch, während das 
Gen in Tumorzellen nicht transkribiert wurde. Resultierende Schnittprodukte konnten in wt-
p53-Zellen aber nicht in p53-negativen Zelllinien nachgewiesen werden. Die Replikation I-
Sce I-kodierender Viren wurde durch diesen Schalter im Gegensatz zu entsprechenden EGFP-
Kontrollviren ausschließlich in p53-postiven aber nicht in p53-negativen Zelllinien gehemmt. 
Außerdem war der I-Sce I-Schalter mit einem weiteren transkriptionellen Repressor-
mechanismus (Gal4-KRAB) kombinierbar. Als Ergebnis wurden stark regulierte, konditionell 
replizierende Adenoviren entwickelt, die zwei neuartige Regulationsmechanismen 
kombinieren, um die Sicherheit der onkolytischen Therapie solider Tumoren zu erhöhen. 
Darüber hinaus wurde die Apoptose-Induktion durch VSV mit speziellem Fokus auf Proteine 
der Bcl-2-Proteinfamilie untersucht. Das Proteinniveau von Mcl-1 (myeloid cell leukemia 1) 
sank in VSV-infizierten Zellen schnell und stark ab, was auf der VSV-induzierten Hemmung 
der zellulären Proteinbiosynthese bei gleichzeitig fortgesetzter proteasomaler Degradation 
von Mcl-1 basiert. Die Expression von stabilisiertem Mcl-1-Protein führte zur Hemmung der 
Apoptose-Induktion. Die VSV-induzierte Eliminierung von Mcl-1 konnte in vitro und in vivo 
ausgenutzt werden, um die Wirkung einer chemotherapeutischen Therapie zu verstärken. 
Daraus ergibt sich, das Mcl-1 einen anti-viralen Schalter darstellt, der zudem für eine 
verstärkte Tumortherapie in vitro und in vivo ausgenutzt werden kann. 
 
Stichworte: Onkolytische Viren, Apoptose, Mcl-1 
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3. Introduction 
 
The development of biological science during the last decades allows the 
complementation of traditional treatment regimens by more targeted therapies. 
Virotherapy represents an innovative approach to treat human malignancies by 
viral means. Both a thorough understanding of the disease itself and the virus-host-
interactions can lead to concepts where certain viruses are engineered to permit 
cure of patients at high safety standards and increased success rates compared to 
standard therapies. In the work presented here, questions regarding both basic 
research on virus-host-interactions and applied virotherapy were addressed.  
 
3.1 Cancer and tumor development 
 
3.1.1 Cancer 
 
Cancer can be described as a group of diseases underlying one basic phenomenon: 
uncontrolled cell growth. In contrast to normal, differentiated cells that have lost 
their replicative capacity, cancer cells have regained the potential for unlimited 
cell division. Although many differences in genotype and phenotype of different 
cancers have been observed, there is ample evidence that the emergence of all 
cancers can be explained by a common set of only a few molecular alterations [1]. 
It was noted therefore, that neoplasms generally develop in the same way and 
show the same general behavioral characteristics [2].  
Solid tumors are cell masses that lack liquid areas and can be non-cancerous 
(benign) or cancerous (malignant). Often, a complex, integrated organ-like 
structure can be observed that comprises interstitial connective tissue, blood 
vessels and extra-cellular matrix [3;4]. This appearance has several implications 
for the treatment of solid tumors since accessibility for anti-cancer therapeutics is 
highly limited by encapsulation and fragmentation of the tumor by stromal 
components – a fact called physiological resistance [5;6]. Thus, therapeutic 
success in the treatment of malignant solid tumors especially in comparison to 
non-solid cancers needs to be improved. As conventional therapies only showed 
limited success, new strategies taking into account current knowledge of cancer 
development might pose promising alternatives. 
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3.1.2 Model of tumor development 
 
In multi-cellular organisms the organization of cells within tissues and organs is 
strictly regulated. As all mammalian cells carry similar molecular programs 
regulating their proliferation, differentiation and death, dysregulation of these 
molecular circuits might lead to the transformation of normal into malignant cells. 
Based on the observations of human cancers and animal models it was proposed 
that four to seven rate-limiting, stochastic events [7] suffice for the development of 
tumors. On the basis of genetic instability, tumor cells acquire up to six alterations 
that collectively dictate malignant growth: (I) self-sufficiency in growth signals, 
(II) insensitivity to growth-inhibiting signals, (III) limitless replicative potential, 
(IV) evasion of programmed cell death (apoptosis), (V) neoangiogenesis, and (VI) 
tissue invasion and metastasis (reviewed in [1]). Noteworthy, ancillary cells like 
fibroblast and endothelial cells as well as extracellular matrix components present 
in a tumor play a key role in driving tumor development by cell-to-cell signaling 
[1]. Furthermore, cancer phenotype is very much dependent on maintenance of the 
established modifications, a phenomenon termed “oncogene addiction” [8].  
Several barriers restricting tumor transformation have been observed in 
mammalian cells. Replicative lifespan of somatic cells usually is limited by lack of 
telomerase activity [9]. Telomeres are repetitive DNA sequences at the end of 
eukaryotic chromosomes with protective character to prevent end-to-end fusion 
with other chromosomes. During cell division telomeres are shortened and after 
continuous erosion the cell responds by entering the state of senescence. If those 
senescent cells harbor inactive retinoblastoma protein (RB) and tumor suppressor 
protein p53 pathways they regain ability to multiply until facing a state of massive 
cell death and karyotypic disarray termed crisis. Only a small number of cells is 
able to overcome the crisis, thereby acquiring unlimited replicative potential and 
reach the state of immortalization [10]. 
Genetic modifications (mutations, chromosomal aberrations) and epigenetic 
abnormalities promote cancer development in two ways: by inactivating genes that 
act as tumor suppressors like retinoblastoma protein (RB) and adenomatous 
polyposis coli (APC), and by transforming proto-oncogenes lsuch as Ras or certain 
receptor tyrosine kinases. While latter affect the proliferative and/or differentiation 
state of cells, tumor suppressor proteins represent cellular checkpoints that drive 
cells into apoptosis upon detection of abnormal intracellular conditions (e. g. 
3. INTRODUCTION  5 
   
oncogene activation or DNA damage). The most prominent tumor suppressor 
protein is p53. This protein is involved in various processes that maintain genomic 
stability (suggesting a role as “guardian of the genome” [11]), induction of 
temporary or irreversible growth arrest and cell death [12;13]. Additionally, p53 
was demonstrated to influence innate immunity [14;15] and angiogenesis [16;17]. 
p53 unfolds its actions by protein-protein interactions and especially by its ability 
to act as transcription factor [12;13]. p53 responsive genes possess pro-apoptotic 
(Bax, Fas), cell cycle control (p21WAF1/CIP1, PCNA) and DNA repair activity 
(GADD45). This paramount position of p53 makes it a preferential target for 
functional inactivation necessary for tumor development. As a result, genetic 
modifications (homozygous deletion, mutation) of the p53 gene and altered p53-
regulating pathways can be observed in the majority of human tumors [18]. 
Notably, as p53 simultaneously is involved in anti-tumor and anti-viral defense, 
many viruses (e.g. Adenovirus) inactivate p53 to prevent premature induction of 
apoptosis to allow for productive viral amplification.  
The connection between anti-viral and anti-neoplastic pathways can be highlighted 
by the interferon (IFN) system. Interferons are multifunctional cytokines that are 
involved in cell growth, apoptosis, and anti-viral pathways. During tumor 
development, the selection pressure for relentless growth and insensitivity toward 
apoptosis might favour cells that inactivate the interferon system resulting in loss 
of expression of key interferon genes [19]. In contrast, tumors that disrupt the IFN 
system might be more susceptible to viral threats. Surprisingly, it has recently been 
reported that interaction of α/β-interferons and p53 cooperate in fighting viral 
infections [14;15]. 
A hallmark of tumor development is the resistance toward cell death signals as 
almost all cancers acquire this property during the transformation process. 
Apoptosis – termed programmed cell death I – appears in all metazoans. It is 
essential to maintain tissue homeostasis and ensure successful organogenesis. 
Following a precisely choreographed series of steps the morphological 
manifestations of apoptosis will be apparent: disruption of cellular membranes, 
break-down of cytoskeleton, extrusion of the cytoplasm, degradation of 
chromosomes by endonucleolytic cleavage of DNA and condensation of the 
nuclear compartment [20]. The components of the apoptotic machinery can 
roughly be divided into sensors and effectors. Sensors control the extra- and 
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intracellular environments for cell death promoting signals and subsequently 
regulate components functioning as effectors of apoptosis. While one axis of 
apoptosis – the so called extrinsic pathway – processes extracellular signals (e.g. 
FAS ligand, TNFα) eliciting cell death in a sometimes mitochondria-independent 
manner, the intracellular arm – termed intrinsic pathway – senses and transmits 
signals from within the cell. Finally, the majority of signals converge on the 
mitochondria that respond by releasing cytochrome C, a potent catalyst of 
apoptosis [21]. This process is tightly regulated by members of the Bcl-2 family of 
proteins. Consisting of three subgroups – classified by structural charateristics – its 
members possess apoptosis-promoting (Bim, Puma, Noxa, Bax, Bak) or anti-
apoptotic (Bcl-2, Bcl-xL, Mcl-1) functions. The cooperation of these members is 
crucial for balancing survival and cell death but is not yet fully understood [22]. 
Certain intracellular proteases (caspases) ultimately act as executors of apoptosis. 
Hierarchically arranged in the process of apoptosis execution, initiator caspases 
activate effector caspases that selectively destroy cellular structures, the organelles 
and the genome of the cell [23]. 
 
3.1.3 Therapeutic treatment strategies 
 
Conventional therapeutic strategies like radiation or anti-neoplastic chemotherapy 
primarily affect tumor tissue but their rather unselective action and leads to harsh 
adverse effects to neighboring tissue or even the whole patient. This brute-force 
approach was refined over years and significant progress could be achieved 
especially for non-solid tumors. Chemotherapies today target the high growth rate 
of cancer cells. Nonetheless, even the emergence of modern biologicals like 
therapeutic antibodies eventually could not prove to cure cancer patients but rather 
provides a limited survival advantage at higher quality of life. 
Taken together, great advances in cancer therapy have been achieved over the last 
60 years since Farber’s introduction of aminopterin as one of the first 
chemotherapeutics [24]. Unfortunately for certain cancers – especially solid 
tumors – the outlook often remains fatal as conventional therapies are not capable 
to eradicate the entire tumor. At this point, the concept of oncolytic virotherapy 
addresses the major drawback of these therapies: conventional therapies lack the 
capacity to extinguish the whole tumor entity. Therefore, oncolytic viruses are 
tailored, replication-competent viruses aimed to specifically kill tumor cells by 
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concurrently propagating to amplify the anti-tumor agent itself. Selectivity of these 
oncolytic viruses is achieved by exploiting oncogenic features or pathways of 
cancerous cells. Ideally, the viral propagation stops and virus is cleared from the 
body when the last susceptible tumor cells are killed. An idealized concept of 
virotherapy is schematically depicted in figure 1 and explained in detail in the 
following chapters. 
 
 
 
Figure 1. Theoretical concept of virotherapy. The therapeutic virus is injected into the 
patient and primarily targets cancer cells. Destruction of the infected cell and release of 
viral progeny allow infection malignant tumor tissue. As therapeutic viruses should be 
highly selective for cancer cells, healthy tissue is spared from cell lyses. When destruction 
of the tumor is completed, viral propagation comes to an end and remaining viral particles 
are cleared from the patient by immune cells. Particles that infected normal tissue will 
remain idle without causing viral replication and cell lysis. 
 
 
 
 
3.2 Virotherapy 
 
3.2.1 Development of cancer therapies by viral means 
 
With more than 2,400 known species viruses represent a vast biological resource. 
Usually known to cause severe illnesses ranging from infectious diseases to 
cancer, perception is not only recently emerging that these ‘miniature biological 
machines’ or ‘nanoparticles’ can be exploited to serve in the fight against several 
sicknesses [25;26]. First case reports documenting tumor regression coinciding 
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with naturally acquired viral infections go back to the mid-1880s [27;28]. 
Suggestions aiming at exploiting viruses for therapeutic use arose at the beginning 
of the 19th century, but only in the late 1940s first clinical experiments were 
performed [29]. A hallmark of virotherapy is represented by the studies of Moore 
who used newly developed rodent cancer models to show that a virus (Russian Far 
East encephalitis virus) can selectively kill cancer cells in vivo [30;31]. Among 
Hepatitis viruses, Epstein-Barr virus, flaviviruses and others, Adenoviruses were 
identified as oncolytic agents in the 1950s (then known as adenoidal-pharyngeal-
conjuctival virus) [32]. To control virulence and escape rapid clearance of the 
oncolytic agent by the patient’s immune system because of earlier encounters 
much attention was drawn on animal viruses resulting in the discovery of several 
so called naturally tumor viruses. Nonetheless, only Newcastle Disease Virus 
(NDV) [33] and Vesicular Stomatitis Virus (VSV) [34] have been pursued as 
natural oncolytics today. With the advent of reverse genetics, direct manipulation 
of viruses became feasible to target viruses more specifically to cancerous cells. 
Subsequent to the generation of non-replicative viruses the potential of replication-
competent agents was recognized. Eventually, this resulted in the first market 
approval for H101, a genetically modified human Adenovirus type 5, in 2005 for 
combination treatment with chemotherapy of patients suffering from head and 
neck cancer [35].  
In the following chapter an introduction to therapeutically exploited viruses is 
provided that focuses on the molecular background of replicative oncolytic viruses 
and strategies to increase their tumor selectivity in general (3.2.2). Subsequently, 
special attention is paid to human Adenoviruses (3.3) and Vesicular Stomatitis 
Virus (3.4) applied as virotherapeutic agents. 
 
3.2.2 Strategies for the exploitation of viruses as oncolytic agents 
 
The application of viruses for the treatment of human patients requires a high level 
of safety. Therefore, an oncolytic virus should display two properties: selective 
propagation in and destruction of tumor tissue while sparing normal cells. This not 
only includes a high specificity for cancer cells, but also the evolution of a 
therapeutic virus into a pathogen within the patient has to be prohibited.  
While some viruses display a natural specificity for cancer cells, others have to be 
engineered to increase therapeutic efficacy. The underlying targeting principles – 
3. INTRODUCTION  9 
   
irrespective of the oncolytic virus applied – can be reduced to four groups: 
transductional, transcriptional, translational and apoptosis targeting (reviewed in 
[26]). 
Transductional targeting includes different strategies to restrict entry of oncolytic 
viruses to cancer tissue. Other concepts allow infection of non-cancerous cells but 
aim to prevent viral replication by regulating transcription of viral key proteins 
(transcriptional targeting). Cells have developed different mechanisms to react on 
viral infections. During tumor development, cancer cells inactivate some of these 
anti-viral pathways what has been reported for the interferon system for example 
[36]. Thus, certain viruses preferentially replicate in cancer tissue exploiting the 
loss of anti-viral barriers. In contrast, normal cells block translation of viral 
mRNAs (translational targeting). Another concept is the modification of viral 
genes whose products are essential for virus propagation in normal cells but are 
dispensable in tumor cells (apoptosis targeting) [37]. 
 
 
3.3 Adenoviruses as oncolytic agents 
 
The family of Adenoviridae comprises non-enveloped viruses with a linear, non-
segmented, double-stranded DNA (30 – 38 kb) as genome. Until today, more than 
40 species of Adenoviruses are known to infect animals and men. Currently, there 
are over 50 serotypes known that infect humans primarily being responsible for 
mild diseases of the upper respiratory system but also for conjunctivitis and 
gastroenteritis. On the other hand, these viruses pose a major threat to immune-
compromised patients causing severe problems with high rates of mortality. First 
described in 1953 [32], Adenoviruses are well studied today. Adenoviral DNA is 
not integrated into the host genome, consequently risk of virus-induced 
mutagenesis is low, and particles can be produced of high titers and purity. Thus, 
certain adenoviral subtypes have been developed as anti-cancer therapeutics – so 
called oncolytic Adenoviruses [38-42]. So far, the adenoviral vectors called 
Gendicine (2003) – a non-replicative virus containing the tumor suppressor gene 
p53 – and H101/Oncorine (2005) – a modified replication-competent vector for 
oncolytic therapy – are the only viruses that have been approved for treating 
human cancers [35;43].  
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3.3.1 The human Adenoviruses type 5 
 
To infect target cells human Adenovirus type 5 relies on the presentation of the 
coxsackievirus adenovirus receptor (CAR) on the surface of cells. CAR is bound 
by the knob domain of the adenoviral fiber protein. Additional binding to the co-
receptor αV integrin (CD51) results in endocytosis of the virus particle via 
clathrin-coated pits. The virion is released to the cytoplasm by acidification of 
endosomes and subsequent structural changes of the capsid. Exploiting 
components of the cytoskeleton, the virion is transferred to nuclear pores where 
the viral DNA is released into the nucleus.  
The replication cycle of Adenoviruses consists of an early and a late phase in 
which distinct gene products are expressed. Early genes (E1 – E4) possess 
regulatory functions: first, host cell gene expression is altered to allow for viral 
DNA synthesis; second, premature cell death of an infected cell by innate or 
adaptive immune defense mechanisms is prevented; and third, other viral genes are 
activated [44]. Genes from the E1 locus are separated into E1A and E1B genes that 
both express various splice variants. These two early gene families are most 
prominent in modifying the infected cell to promote viral replication. E1A 
activates adenoviral transcription and targets RB family members to drive the host 
cell into S phase of the cell cycle. As the actions of E1A induce pro-apoptotic 
signals, E1B variants, like E1B-19k (a viral Mcl-1 mimic) and E1B-55k, inhibit 
apoptosis by sequestering p53 in the cytoplasm [45], impairing p53 function as 
transcriptional activator (E1B-55k) [46;47] and by inactivating pro-apoptotic Bax 
and Bak proteins (E1B-19k) [48;49]. In conjunction, these proteins are able to 
immortalize and transform primary cells in vitro [50]. Replication of the viral 
genome occurs with the terminal protein acting as primer by covalently binding to 
the 5’-ends of the genome. For adenoviral replication, entry of the host cell into S 
phase is a prerequisite [44]. In the late phase structural proteins for packaging the 
viral genome are produced. Assembly of viral particles occurs in the nucleus of the 
infected cell that is finally lysed to release infectious virions.  
 
3.3.2 Adenoviruses as oncolytic vector 
 
The fact that Adenoviruses are DNA viruses with a relatively small genome 
facilitated its application as genetically modified therapeutic agent. There have 
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been several developmental waves of recombinant Adenoviruses generated for the 
treatment of human diseases. First-generation vectors were rendered replication-
deficient by deleting E1 or both E1 and E3 region. Usually, these vectors were 
used to express therapeutic genes [51;52]. To minimize immunogenicity and to 
increase cloning capacity, second-generation vectors were constructed that 
additionally lack E2 and E4 genes. This trend finally led to third-generation 
adenoviral vectors – also termed gutless vectors – that completely lack the viral 
genomic information except of the inverted terminal repeat sequences (ITR) and 
the viral packaging signal [53].  
Since these vectors did not lead to satisfyingly therapeutic efficacy, replication-
competent Adenoviruses were constructed. Replicative vectors can elicit cell death 
in human cancer cells by different mechanisms: cytotoxicity mediated through 
viral proteins, induction of antiviral immunity, sensitization to chemotherapeutics 
or expression of heterologous therapeutic genes [38]. Limitation of side-effects 
while retaining oncolytic potential and the capacity to replicate efficiently can be 
achieved by targeting recombinant Adenoviruses to cancer cells by certain means. 
Adenoviruses can be transductionally targeted by replacing attachment proteins 
responsible for the native viral tropism. This can be necessary not only to gain 
selectivity but also because cancer cells often reduce or completely shut down 
expression of the native Adenovirus surface receptor CAR [54]. Additionally, 
tumor-selectively replicating adenoviral vectors were generated by modification of 
viral genes [40;55], repression of cellular genes that have essential character for 
virus replication [56] or even tumor-specific genome rearrangements of viruses 
[57]. Transcriptional control of adenoviral genes by tumor- or tissue-specific 
promoters (such as MUC1, AFP, PSA, kallikrein-2, pS2, alpha-lactalbumin, 
CXCR4, hTERT or Flk-1/endoglin) is another powerful tool to restrict replication 
to cancer cells [58-66]. Unfortunately, application of these promoters strongly 
narrows the virus to a certain cancer or tissue. However, the exploitation of a more 
general tumor feature would greatly broaden the field of application for 
transcriptionally targeted viruses.  
 
3.3.3 p53-dependent adenoviral vectors 
 
Since the tumor suppressor protein p53 is impaired in the majority of human 
tumors by genetic alterations, decreased protein stability or other mechanisms [67-
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71] its transcriptional status (active or inactive) could be applied to differentiate 
between cancerous and normal cells and, thus, increase tumor-selectivity while 
potentially treating a wide range of tumors. In pioneering works it was 
hypothesized that deleting the p53-binding protein E1B-55k would restrict viral 
replication to cells with genetic defects in the p53 pathway [55]. However, p53-
dependency of the resulting adenoviral vector Addl1520 (Onyx-015) was 
questioned. Rather, differential late viral mRNA export seems to be determining 
selectivity of Onyx-015 [72].  
 
 
Figure 2. Schematic representation of the p53-dependent regulator system as part 
of the adenoviral genome. (A) Within an adenoviral backbone the p53-dependent 
promoter prMin-RGC drives the expression of the regulator gene Gal4-KRAB in presence 
of p53. The Gal4-Domain of the fusion protein binds to specific DNA-binding sequences in 
the artificial CMV promoter that controls expression of the E1A gene. Following, the 
KRAB-domain acts as a transcriptional repressor and E1A is not expressed. (B) In 
contrast, when p53 is absent or inactivated (like in the majority of human tumors) prMin-
RGC is inactive and, thus, E1A is transcribed and subsequently can start viral replication 
finally leading to viral offspring and lysis of the infected cell. 
 
 
In an alternative concept (figure 2), an artificial p53 dependent promoter called 
prMin-RGC has been constructed that allows for selective expression of genes in 
p53 wild type cells [73;74]. This promoter contains thirteen p53-binding sites 
derived from the ribosomal gene cluster (RGC), in combination with a minimal 
CMV-promoter providing a TATA-box motive. In a replication-competent 
Adenovirus, prMin-RGC controlled the expression of the transcriptional repressor 
fusion protein Gal4-KRAB (Gal4-DNA binding domain fused to the KRAB 
repressor). Gal4-KRAB in turn repressed E1A expression in p53 positive cells by 
binding to an artificial Gal4-KRAB-dependent CMV promoter that controls the 
expression of E1A. In absence of functional p53, Gal4-KRAB is not expressed, 
thus, allowing expression of E1A that promotes viral replication [74]. Supporting 
this strategy, in cells expressing functional p53 the protein level can be further 
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elevated by chemotherapy, e.g. Doxorubicin treatment. Furthermore, Adenoviruses 
itself stabilize p53 [75], thus enhancing prMin-RGC-controlled expression. To 
facilitate comprehension, the concept is depicted in figure 2.  
 
3.3.4 The endonucleolytic enzyme I-Sce I 
 
A replication deficient adenoviral vector was developed that expresses the rare-
cutting endonuclease I-Sce I [76]. In contrast to virotherapeutic approaches this 
concept focuses on DNA repair and gene targeting by generating specific DNA 
double strand breaks. Nonetheless, this enzyme might be suitable to increase 
selectivity of conditionally replicating Adenoviruses when applied in the right 
setup. 
 
 
Figure 3. I-Sce I recognition sequence. The 18 base pair long recognition sequence of 
I-Sce I is non-palindromic and therefore can be described in forward and reverse direction. 
Cleavage (red lines) results in two parts that differ in length. The icons on the right side 
will be employed in following figure. 
 
 
The meganuclease I-Sce I is a 26 kDa site-specific homing-endonuclease encoded 
by a mitochondrial intron of Saccharomyces cerevisiae [77-79]. Homing nucleases 
recognize long nucleotide sequences (14 – 40 bp) and therefore represent a class of 
extremely rare cutting enzymes. The core cleavage sequence of I-Sce I was 
revealed as a non-palindromic 18 bp long sequence [78] depicted in figure 3. On a 
random basis, this 18 bp sequence can be found as one in 70 billion base pairs (418 
bp), thus, allowing the introduction of a single or several cleavage sites into 
complex genomes, e.g. oncolytic DNA viruses. This capability makes the enzyme 
not only a powerful tool for the study of DNA repair processes [80;81] but also 
provides a smart instrument for targeted genome engineering in nearly all 
organisms like for example recombinant adenoviral vectors. Most likely, acceptor 
organisms are not affected by I-Sce I expression [82]. 
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3.4 Vesicular Stomatitis Virus (VSV) 
 
Vesicular Stomatitis Virus (VSV) is a bullet-shaped member of the Rhabdovirus 
family that causes a contagious disease among a broad range of host species 
including horses, cattle, and pigs [83], whereas the infection in humans is usually 
asymptomatic. In contrast, non-lethal infections of animals provoke lesions in the 
mucosa of nose and mouth and intranasally infected mice even suffer from 
neuropathy since neurons are highly susceptible for VSV infection. Naturally 
occurring in Latin America, VSV repeatedly caused epizootic diseases in the USA 
[84]. Serological analysis revealed the existence of at least two VSV serotypes 
known as New Jersey (VSV-NJ) and Indiana (VSV-IN) subtype [85].  
 
3.4.1 Structure of Vesicular Stomatitis Virus 
 
VSV is an enveloped virus with a non-segmented 11 kb long negative-stranded 
RNA genome that encodes five primary gene products, the nucleocapsid (VSV-N), 
polymerase proteins, (VSV-L) and (VSV-P), surface glycoprotein (VSV-G) and a 
peripheral matrix protein (VSV-M) [86]. Viral replication proceeds in the 
cytoplasm of infected cells. VSV does not undergo genetic recombination or 
reassortment. It neither and possesses known transforming potential nor it does 
integrate parts of its genome into the host DNA [87]. These properties make VSV 
attractive for use as therapeutic agent for humans.  
VSV-G is the major known antigen and is densely packed on the viral surface. As 
a consequence, intact virions exhibit only one antigenic site that is a target for 
neutralizing antibodies in vivo [88]. VSV-N encases the viral genome but 
polymerase proteins L and P are attached to the RNA as well. The multifunctional 
VSV-M protein binds to viral components like RNA genome/nucleocapsid core 
(RNP) and VSV-G. On the other hand, the matrix protein is the major component 
of VSV responsible for interactions with the host cell (as described below).  
 
3.4.1.1 Replication cycle of VSV 
 
The infection cycle of the Vesicular Stomatitis Virus (VSV) starts with the binding 
of the glycoprotein to a yet unidentified receptor on the surface of the target cell. 
According to the broad range of infected cell types including mammalian as well 
as insect cells, the receptor is supposed to be an ubiquitously occurring molecule 
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that acts as binding partner for VSV-G [89]. So far, it is known that phosphatidyl 
serine is required for endocytosis but it has been excluded to serve as prime 
surface receptor of VSV [90]. In the cytoplasm of the infected cell viral 
polymerase proteins carried within the virus capsid start sequential transcription of 
the five viral genes resulting in capped and polyadenylated RNAs that are 
translated by the host cell’s translation machinery [91;92]. Interestingly, the 
proteins generating the subgenomic RNAs are also responsible for the replication 
of the RNA genome. Newly synthesized N, P and L proteins associate with 
genomic RNA, thus forming RNP cores. These cores bind to regions of the cell 
membrane that are enriched with viral G and M proteins. Viral offspring will be 
released by budding that is followed by cell destruction. In comparison to other 
viruses VSV generates a tremendous amount of viral progeny within a short period 
of time. 
 
3.4.1.2 Virus-host-interactions 
 
3.4.1.2.1 VSV replication is highly susceptible to the actions of type I interferons 
 
Host cells facing a viral infection usually limit viral amplification by activating 
components of the immune system. The adaptive immunity clears virus infected 
cells and neutralizes free-floating virus. But even on the cellular level an arsenal of 
anti-viral mechanisms is available that have an adverse effect on virus replication. 
These mechanisms are part of the innate immune response that when altered 
renders cells highly susceptible to viral threats and also plays a crucial role in 
cancer development. A functional adaptive immune response can not compensate 
an impaired innate immunity since animals lacking innate immunity components 
die from the cytopathic nature of VSV infection. 
VSV is called a natural tumor virus or naturally smart virus as it is lytic to 
numerous transformed and malignant cell lines and much less so to normal tissue. 
It could be shown that VSV is extremely sensitive to the anti-viral action of the 
type I interferons [34;93]. The interferon (IFN) system mediates host defense by 
utilizing several components that sense a viral infection, promote signal 
transduction and affect virally transduced and uninfected neighboring cells. 
Signaling components like the Toll-like receptor pathway, the NF-κB pathway and 
interferon-regulatory factor 3 (IRF-3) initially sensing the infection by a virus 
induce transcription and secretion of IFN-β. Interferon α/β receptors (IFNARs) 
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transmit the signal to the Jak/STAT pathway which finally leads to the 
transcription of IFN-stimulated genes (ISGs) that provide an antiviral response 
[34;94]. Not surprisingly, VSV’s selectivity to human tumor cells is based on the 
fact that IFN-responsive pathways are often defective in human cancers 
[34;93;95;96]. In contrast, functional IFN pathways in normal cells limit VSV 
amplification by induction of a robust anti-viral response. Namely, type I 
interferons highly restrict transcription of subgenomic mRNAs [97;98], mRNA 
cap methylation [99], mRNA translation [100;101] and viral assembly [102]. 
Research on virus-host interactions revealed several key components of the IFN 
system to fight VSV which will be briefly described below. 
The eIF2α kinase PKR has been considered a crucial checkpoint against viral 
infections in general as it shuts down protein biosynthesis via phosphorylation of 
the eukaryotic initiation factor 2 (eIF2α) and elicits an apoptotic response after 
binding to the extensive secondary structures of double-stranded RNA (dsRNA). 
The role of PKR within the defense line against VSV is discussed controversially. 
VSV induces activation of PKR and mice lacking the interferon-inducible double-
stranded RNA-dependent protein kinase are reported to be highly susceptible to 
VSV infection in comparison to wild type mice [103;104]. Other studies support 
this point of view [105-107] while more recent publications are questioning the 
role of PKR as a major component of IFN-mediated resistance to VSV infection. 
Rather, two other members of the eIF2α kinase family, the general control non-
derepressible-2 (GCN2) protein and the endoplasmic reticulum (ER) kinase 
PERK/PEK which is activated by the presence of unfolded protein in the ER, are 
shown to exclusively contribute to the inhibition of VSV replication [108;109]. 
Additionally, while VSV can trigger IFN induction by recognition of single-
stranded RNA via toll-like receptor 7 (TLR7) [110;111] there was no dsRNA 
detectable in VSV infected cells – although being expected to emerge within the 
replication of the genomic RNA – that might have induced activation of PKR 
suggesting that other viral components are more relevant for the induction of an 
anti-viral response [112].  
Other members of the IFN-mediated anti-viral mechanisms that were reported to 
play a certain role in fighting VSV infections are the interferons themselves 
[113;114] and Stat-1 [115] suggesting the IFN system to be a key mechanism for 
the defense against VSV infections. 
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Interestingly, ISGs not only act anti-virally but concomitantly play a physiological 
role in preventing cancer development [36]. For example, induction of the tumor 
suppressor p53 was reported following interferon treatment [14] suggesting a 
possible anti-viral activity of p53. Although no VSV-associated mechanism is 
known that specifically targets p53 to abrogate its function – a common feature 
among viruses – two recent studies provide evidence of limiting VSV 
amplification by p53. Upon infection of mouse embryo fibroblasts (MEF) with 
VSV p53 is phosphorylated in an ataxia telangiectasia mutated (ATM)-dependent 
manner at Ser18 and subsequently leads to the transcription of p53 target genes 
[14]. Noteworthy, p53 up-regulation is dependent on the interferon α/β receptor 
(IFNAR) indicating a strong link between p53 and IFN pathways. Compared to 
p53-/- MEFs, wild type cells underwent a rapid induction of apoptosis, thus 
limiting viral production. In vivo, deletion of p53 renders mice susceptible to low 
doses of VSV while wild type mice remain unaffected. Questioning the pleiotropic 
effects of an absence of p53 on antiviral responses another group observed a 
limited VSV propagation in mice bearing an additional copy of the p53 gene 
(“super p53 mice”) and did explain it by an enhanced p53-dependent induction of 
apoptosis [116]. However, posing a significant effect in MEFs in vitro (virus yield 
in wild type mice was 10-fold higher than in super 53 mice and at certainly lower 
apoptotic levels) the survival rate of infected wild type and super p53 mice did not 
show statistical differences [116].  
 
3.4.1.2.2 VSV usurps the cellular protein biosynthesis machinery 
 
Although coding for only five proteins, VSV massively modulates protein 
biosynthesis of the infected cell including transcription, the export of mRNAs and 
translation. It has been reported that the multi-functional matrix protein of VSV 
inhibits the cellular RNA-polymerases I-III [117;118] preventing generation of 
mRNAs. By binding to the mRNA export factor Rae1, transfer of mRNAs to the 
cytoplasm is efficiently suppressed [119]. Another component of the host cell 
translation machinery that is primarily targeted to limit protein biosynthesis of the 
infected cell is a part of the multi-subunit eIF4F complex, termed eIF4E. VSV-
mediated dephosphorylation of eIF4E at serine 209 (via dephosphorylation of the 
eIF4E-binding protein 4E-BP-1) between 3 and 6 h post infection leads to the 
disassembly from the eIF4F complex resulting in a block of translation of host 
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mRNAs [120]. Thus, it has been reported that inhibition of interferon genes is 
achieved by general inhibition of host RNA and protein synthesis [121]. Despite 
this, the translation of viral 5’-capped mRNAs proceeds since viral mRNAs 
contain cis-acting structural elements that enhance translation efficacy of viral 
mRNAs [122]. This grants the virus exclusivity to cellular resources. By 
phosphorylation of the alpha-subunit of eIF2α infected cells can react on this 
hijacking of the cellular translation apparatus by blocking global translation. It 
should be noted, that in contrast to normal cells, the guanine nucleotide exchange 
factor eIF2B downstream of eIF2α was frequently aberrant in human tumors, 
reversing eIF2α activity and finally allowing VSV mRNA translation [96], and 
thus posing another selectivity mechanism for VSV.  
 
3.4.1.2.3 Induction of apoptosis in VSV-infected cells 
 
During evolution, many viruses have acquired mechanisms to interfere with 
induction of apoptosis, a major reaction of infected cells to limit viral spread. VSV 
infected cells induce apoptosis in a caspase-3/9-dependent manner [93;95;123-
127] wherein the pro-apoptotic Bax protein might represent a central point of 
convergence finally leading to mitochondrial membrane depolarization [128]. 
Mechanisms to prevent this induction are not known so far. However, it can rather 
be speculated whether this rapid induction by a virion constitutive component 
[125] could be beneficial for the virus. As wild type VSV induces apoptosis via the 
mitochondrial (intrinsic) pathway, it has been analyzed whether members of the 
Bcl-2 family influence viral amplification. For the pro-survival members Bcl-2 and 
Bcl-xL it was shown that over-expression promoted survival of infected cells of 
neural origin [126]. VSV-mediated apoptosis can even be partially suppressed by 
over-expression of Bcl-2 [126]. For currently developed VSV-M mutants that 
show a more promising safety profile than their wild type counterparts, natural 
Bcl-2 over-expression observed in primary chronic lymphocytic leukemia cells 
prevents the oncolytic effect of the viral therapeutic [129]. 
VSV causes a visible cytopathic effect characterized by the typical rounding of 
infected cells. This is due to the action of the matrix protein that disorganizes 
actin, microtubles and intermediate filaments in cooperation with the VSV-L 
protein [130;131]. This action of VSV-M is strongly correlated with its ability to 
shut down host gene expression [132]. Moreover, VSV disrupts cell-signaling 
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pathways such as STAT signaling probably attenuating inflammatory responses to 
VSV infection [133]. Another effect related to innate immunity is the suppression 
of antigen presentation by VSV-M [134]. Taken together, mainly – but not 
exclusively – by the multiple abilities of the M-protein, VSV hijacks the infected 
cell to transform it into a virus production factory. Due to these diversified roles of 
the matrix protein in VSV replication and pathogenesis it has even been termed the 
‘brain’ of the virus [135]. 
 
3.4.2 VSV as oncolytic vector 
 
The rapid replication cycle, the natural selectivity for tumor cells and the ability to 
infect a wide variety of human cancer cells make VSV an attractive tool for cancer 
therapy. Wild type VSV was repeatedly reported to cause growth inhibition on 
human cancer cell lines exploiting defects in the innate immune response. 
Additionally, the ability of the virus to kill cancer cells in vivo even when 
administered systemically in immunocompetent mice together with the fact that no 
overt symptoms could be observed in these animals holds great promise for wild 
type VSV as effective oncolytic agent [34;95;136]. Oberserving that interferon 
non-responsive tumors can be eradicated by VSV in vitro and in vivo [34], it 
became apparent that tumors that bear defects in the frontline anti-viral IFN 
system are susceptible for oncolytic VSV therapy [93]. Finally, the development of 
VSV as oncolytic vector was further promoted, first by engineering a DNA-based 
platform to generate recombinant VSV particles [137] and, second by the 
discovery of VSV mutants providing an enlarged therapeutic window as they 
induce a powerful IFN-β response [138].  
Certain mutations of the VSV matrix protein neutralize its abilities to impair the 
IFN response in infected cells. Namely, the resulting attenuated virus (AV) 
mutants AV1 (M51R), AV2 (V221F and S226R) and AV3 (M∆51) possess a 
vastly improved therapeutic index compared to wild type VSV as they potently 
induce an interferon response in neural tissue [94]. Whereas wild type and mutant 
viruses induce IFN-β transcription, in cells infected with mutant VSV these IFN-β 
mRNAs were detectable in the cytoplasm indicating that mutations of the VSV 
matrix protein disrupt the block of export of mature mRNAs to the cytoplasm [94]. 
In contrast to wild type VSV, the above described mutants induce apoptosis via the 
extrinsic pathway by Fas and Daxx [139;140]. 
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A wealth of different concepts regarding engineered VSV particles was established 
aiming at an increased selectivity of VSV for human cancer cells by recombinant 
means. Interestingly, recombinant VSV genomes can accommodate large amounts 
of foreign RNA, a strong prerequisite for successful modification [141]. 
Additionally, inserted genes are usually reported to be expressed at high levels. 
Like other viruses VSV has been armed with pro-drug-converting enzymes, such 
as HSV-thymidine kinase [142] and cytosine-deaminase [143] or 
immunomodulatory genes like interleukin-4 [142]. 
Modification of the viral tropism by replacing the glycoprotein by chimeric Sinbis 
virus surface proteins [144;145] yielded a higher selectivity for certain tumor cells 
by restricting the host cell range to cells exposing specific surface tumor markers. 
Furthermore, surface modifications of VSV influence the recognition of host 
adaptive immunity [146]. The integration of host innate immunity genes (IFN-β, 
IL-12) into the genome of VSV improved specificity and enhanced anti-tumor 
efficacy of the resulting vector by combining oncolytic and immunomodulatory 
strategies [147;148].  
In two recent studies the potential of VSV has been explored to augment an 
enhanced therapeutic effect when combined with conventional chemotherapy 
[149;150]. Both studies demonstrated in vitro and in vivo that VSV replication is 
not impaired by gemcitabine or cisplatin chemotherapy, and enhanced anti-tumor 
activity by combined virochemotherapy could be observed. However, both studies 
could not provide a molecular explanation for enhancement of therapy just 
assuming enhanced apoptosis on a narrow experimental basis. 
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4. Objectives 
 
The presented work is focused on advancing knowledge in the field of virotherapy 
of solid human tumors. First, a conditionally replicating adenoviral vector was 
constructed employing a novel tool to increase selectivity for cancer cells. Second, 
the virus-host-interaction between Vesicular Stomatitis Virus and different human 
cancer cell lines regarding induction of apoptosis was explored paying special 
attention to the members of the Bcl-2 family proteins. 
 
Several approaches to limit replication of oncolytic viruses for the treatment of 
human cancers have been described. However, silenced viral particles lying 
dormant in infected cells can be reactivated to start replication by physiological 
changes within the cell. Thus, destruction of the viral backbone in non-target cells 
would prevent the rise of break-through mutants after long persistence in normal 
cells. Hence, based on a p53-responsive system, a recombinant adenoviral vector 
was constructed to express the yeast endonuclease I-Sce I as a self-destruction 
switch in p53-dependent manner to disrupt the viral backbone and increase 
selectivity of the oncolytic vector. 
 
In a second project, infection of human cancer cells by wild type VSV rapidly 
leads to induction of apoptosis, but the underlying mechanisms are not yet fully 
understood. Previous work on other viruses strongly suggests the implication of 
proteins of the Bcl-2 family to be involved in sensing and reacting to viral 
infections. Here, the focus of the investigation was set on the role of the anti-
apoptotic proteins of the Bcl-2 family in fighting VSV infection. As these proteins 
are reported to confer resistance against chemotherapy, a possible sensitization 
mediated by VSV infection was explored. 
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5. Materials and methods 
 
All experiments were performed in S1 or S2 laboratories at Hannover Medical 
School equipped for molecular biological work. Displayed exclusively are 
substances, devices or methods that might have influenced the outcome or the 
form of the experiments or exceed the status of standard laboratory equipment. 
 
5.1 Materials 
 
5.1.1 Cell lines 
 
5.1.1.1 Purchased/provided cell lines 
 
Cell 
line 
Origin Source Main items 
A549 Human, lung ATCC Adenocarcinoma, 
p53+/+ 
HepG2 Human, liver ATCC HCC, p53+/+ 
Huh-7 Human, liver Japanese Collection of 
Research Bioresources 
(JCRB) 
Hepatoma, mut-p53 
(220C, transcriptionally 
inactive form) 
H1299 Human, lung ATCC NSCLC, p53-/- 
Hep3B Human, liver ATCC HCC, p53-/- 
HEK 
293 
Human, kidney ATCC Expressing adenoviral 
E1A and E1B genes 
BSR 
T7/5 
Hamster, kidney  Matthias Schnell, Max 
von Pettenkofer 
Institut, Munich 
T7-Polymerase 
expressing BHK-21-
derivative 
Phoenix 
cells 
Human, kidney Lars Zender, HZI 
Braunschweig 
HEK 293 based 
packaging cell line for 
generation of retroviral 
particles 
 
All cell lines were maintained in growth medium (DMEM + Glutamax, Life 
Technologies) supplemented with 10 % fetal bovine serum (Life Technologies), 
100 units/mL penicillin and 100 µg/ml streptomycin (Seromed, Berlin, Germany) 
at 37°C in 5 % CO2. BSR T7/5 cells (kind gift of Matthias Schnell, Munich) 
required growth medium plus 4 % tryptose phosphate (Life Technologies). 
 
 
5.1.1.2 Stably transfected cell lines 
 
The following transgenic cell lines were generated in the context of this work: 
 
Parental 
cell line 
Inserted 
plasmid(s) 
Inserted promoter-gene 
combination 
Selection marker 
(concentration) 
pS4871 CMV-wt-hMcl-1 Puromycin (800 ng/ml) 
pS4865 CMV-mut-hMcl-1 Puromycin (800 ng/ml) 
A549 
pS5060 CMV-wt-hMcl-1 Neomycin (600 µg/ml) 
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Parental 
cell line 
Inserted 
plasmid(s) 
Inserted promoter-gene 
combination 
Selection marker 
(concentration) 
pS5070 CMV-mut-hMcl-1 Neomycin (600 µg/ml) 
pS5600 CMV-EGFP Neomycin (600 µg/ml) 
SK301 CMV-YFP-LC3 Neomycin (600 µg/ml) 
A549 
SK301 + 
pS4865 
CMV-YFP-LC3 +  
CMV-mut-hMcl-1 
Neomycin (600 µg/ml) +  
Puromycin (800 ng/ml) 
pS5060 CMV-wt-hMcl-1 Neomycin (300 µg/ml) 
pS5070 CMV-mut-hMcl-1 Neomycin (300 µg/ml) 
pS5600 CMV-EGFP Neomycin (300 µg/ml) 
SK301 CMV-YFP-LC3 Neomycin (300 µg/ml) 
pS5926 Scrambled shRNA Neomycin (800 µg/ml) 
pS5839 shRNA anti-Bax Neomycin (800 µg/ml) 
pS5848 shRNA anti-Bak Neomycin (800 µg/ml) 
Huh-7 
pS5862 shRNA anti-Bax/anti-Bak Neomycin (800 µg/ml) 
HepG2 SK301 CMV-YFP-LC3 Neomycin (800 µg/ml) 
 
Transgenic cell lines were generated by lenti- or retroviral gene transfer and 
propagated in growth medium supplemented with Neomycin (Calbiochem Corp. 
San Diego, CA) or Puromycin (Sigma-Aldrich, Taufkirchen, Germany). 
 
5.1.2 Bacteria 
 
Strain Genetic properties, supplier 
JM109 Modified E. coli safety strain; Gibco; prepared as electro- and 
chemically competent cells 
XL1-blue Modified E. coli safety strain; Stratagene; prepared as electro-
competent cells 
 
Bacteria were grown in LB medium containing Ampicillin (100 µg/ml) or 
Kanamycin (10 µg/ml) over night.  
 
5.1.3 Mice 
 
Strain Properties 
NMRI-
nu/nu 
Female, pathogen-free nude mice aged 6-8 weeks from the 
Central Animal Facilities of Hannover Medical School 
 
5.1.4 Plasmids 
 
5.1.4.1 Provided plasmids 
 
Plasmid Supplier/ 
Source 
Properties 
pBlueScript Stratagene Cloning vector (to sequence DNA fragments), 
used as nonsense-DNA for transfections 
pQCXIP Clontech Retroviral vector for the generation of stably 
transfected cell lines containing a CMV-gene 
of choice – IRES – Puromycin unit 
pQCXIN Clontech Retroviral vector for the generation of stably 
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Plasmid Supplier/ 
Source 
Properties 
transfected cell lines containing a CMV-gene 
of choice – IRES – Puromycin unit 
pGL2 Promega Reporter vector containing the firefly 
luciferase (luc) 
pGL4.12 Promega Reporter vector containing a modified firefly 
luciferase (luc2CP) to respond more rapidly 
and with greater magnitude to changes in 
transcriptional activity 
CMV-lacZ Florian Kühnel Vector containing a lacZ gene controlled by a 
CMV promoter, used to normalize efficiency 
of transfection 
CMV-GFP Florian Kühnel Vector containing an EGFP gene controlled 
by a CMV promoter, used to estimate 
efficiency of transfection microscopically 
Gal4-
KRAB 
(FK2337) 
Florian Kühnel Vector containing the gene of the fusion 
protein of Gal4-DNA-binding domain and the 
KRAB (Krüppel associated box) transcription 
repressor domain 
pAdHM4 Mark A. Kay Plasmid containing the genome of human 
Adenovirus type 5 lacking the E1 (342-3523 
bp) and E3 (28133-30818 bp) regions 
K92 Thomas Wirth Shuttle vector containing the Adenoviral E1 
region where E1B transcription is linked to 
EGFP by an IRES 
NW1187 Norman Woller pBluescript containing a U6-promoter to drive 
shRNA-expression 
SK301 Sarah Knocke pQCXIN containing the gene for the fusion 
plasmid YFP-LC3 [151] 
pVSV-G Norman Woller Plasmid coding for VSV-G controlled by a 
CMV promoter 
NW4739 Norman Woller pLVTHM w/o Xba I site 
pMDL g/p 
RRE 
Norman Woller Helper plasmid for Lentivirus generation 
pMD-G Norman Woller Helper plasmid for Lentivirus generation 
pRSV-Rev Norman Woller Helper plasmid for Lentivirus generation 
psiCHECK-
2 
Promega Vector designed to optimize RNAi target 
sequences by expressing two different 
luciferases: Renilla luciferase (with a multiple 
cloning site situated downstream of the stop 
codon to allow integration of target gene 
sequences) and firefly luciferase (for 
normalization of Renilla luciferase 
expression) 
pRK5.LHA
-Sce1 
Toni Cathomen 
(Charité, 
Institute of 
Viorology, 
Berlin) 
Plasmid containing a codon-optimized 
(humanized) version of the I-Sce I gene with 
N-terminal HA-tag and nuclear localization 
sequences 
FK1212 Florian Kühnel pBluescript vector containing a CMV350-
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Plasmid Supplier/ 
Source 
Properties 
promoter that controls a luciferase gene 
DS122 Florian Kühnel pBluescript vector containing a CMV350-
promoter, an artificial MCS and a poly-
adenylation signal (expression plasmid) 
FK1738 Florian Kühnel pGL-2 vector with p53-dependent prMin-
RGC-promoter driving the expression of 
luciferase reporter gene 
pIRES2-
EGFP 
Clontech Vector to co-express EGFP with a gene of 
choice linked by a internal ribosomal entry 
sequence (IRES) 
pVSV-XN2 Recombinant VSV genome (cloning 
platform) 
pVSV-GM-
CSF 
Recombinant VSV genome including an 
additional GM-CSF gene 
pVSV-
EGFP 
Recombinant VSV genome including an 
additional EGFP gene 
pBS-N Expression vector for VSV-N-protein 
pBS-P Expression vector for VSV-P-protein 
pBS-L 
John K. Rose 
(New Haven, 
CT, USA) 
Expression vector for VSV-L-protein 
FK6570 Florian Kühnel pBluescript vector containing a CMV230 
promoter with Gal4-binding sites upstream 
(15x) and downstream (5x) of the promoter 
pSE1A_1 Nina Strüver N-terminally deleted E1A (66bp) 
pSE1A_2 Nina Strüver Wt-E1A 
pSE1A_3 Nina Strüver N-terminally deleted E1A (66bp), insertion of 
a single BamHI-site 
pSE1A_4 Nina Strüver N-terminally deleted E1A (254bp) 
EG263 Engin Gürlevik NW1187 vector controlling a shRNA against 
EGFP under control of a U6-promoter 
p3xFLAG-
CMV-mut-
Mcl-1 
Xiaodong 
Wang, Dallas, 
TX, USA 
Plasmid containing the sequence of human 
Mcl-1 altered by certain Lys→Ala-changes to 
prevent ubiquitination of Mcl-1 
 
 
5.1.4.2 Constructed plasmids 
 
Plasmid Properties 
DS122-
prMin-RGC 
DS122 with the p53-dependent promoter prMin-RGC replacing 
the CMV promoter 
pS209 Expression plasmid for I-Sce I controlled by prMin-RGC-
promoter 
pS261 Expression plasmid for I-Sce I controlled by prMin-RGC-
promoter with a Kozak sequence and an C-terminal His6-tag 
sequence 
pS432 DS122-prMin-RGC controlling the expression of the Gal4-
KRAB gene 
pS584 K92 with excised IRES-EGFP region 
pS575 Expression plasmid for I-Sce I controlled by prMin-RGC-
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Plasmid Properties 
promoter with a Kozak sequence and an additional MCS 
between promoter and I-Sce I gene 
pS716 pS575 including the IRES from pIRES2-EGFP between 
promoter and I-Sce I gene 
pS725 pS716 with the Gal4-KRAB-sequence inserted between prMin-
RGC-promoter and IRES 
pS1111 DS122-prMin-RGC controlling the expression of EGFP with an 
5’-UTR-situated I-Sce I-recognition site (fw) 
FK6451 pGL2 vector containing the expression cassette: CMV350 – Scefw 
– EGFP – Scefw - luciferase 
FK6456 pGL2 vector containing the expression cassette: CMV350 – Scefw 
– EGFP – Scerev - luciferase 
pS2019 pGL2 vector containing the expression cassette: CMV350 –Scerev 
- luciferase 
pS3075 DS122 coding for the human Bcl-x gene  
pS3208 pS725 replacing the I-Sce I gene by EGFP 
pS3251 pBluescript vector containing a Gal4-KRAB sensitive CMV230 
promoter with an I-Sce I-recognition site (fw) at the 3’-end of 
the promoter fragment 
pS3288 Exchange of the IRES-EGFP module in K92 by an artificial 
sequence containing ATG triplets (one for each reading frame) 
and an I-Sce I-recognition site (fw) 
pS3310 Exchange of the IRES-EGFP module in K92 by an artificial 
sequence containing ATG triplets (one for each reading frame) 
and an I-Sce I-recognition site (rev) 
pS3399 pBluescript vector containing a Gal4-KRAB sensitive hTERT 
promoter with an I-Sce I-recognition site (fw) at the 3’-end of 
the promoter fragment 
pS3704 Exchange of the wt-E1A sequence in pS3310 by a N-terminally 
truncated form (del66) of E1A 
pS3786 Exchange of the wt-E1A sequence in pS3288 by a N-terminally 
truncated form (del66) of E1A 
pS4098 Insertion of the I-Sce I-sensitive CMV230-promoter (pS3251) 
into pS3704 upstream of E1A 
pS4112 Insertion of the I-Sce I-sensitive hTERT-promoter (pS3399) into 
pS3704 upstream of E1A 
pS4116 Insertion of the I-Sce I-sensitive CMV230-promoter (pS3251) 
into pS3786 upstream of E1A 
pS4129 Insertion of the I-Sce I-sensitive hTERT-promoter (pS3399) into 
pS3786 upstream of E1A 
pS4237 Insertion of prMin-RGC-I-Sce I-unit from pS261 into pS4116 
downstream of the E1 genes (CMV, Scefw §) 
pS4226 Insertion of prMin-RGC-I-Sce I-unit from pS261 into pS4098 
downstream of the E1 genes (CMV, Scerev §) 
pS4240 Insertion of prMin-RGC-I-Sce I-unit from pS261 into pS4129 
downstream of the E1 genes (hTERT, Scefw §) 
pS4233 Insertion of prMin-RGC-I-Sce I-unit from pS261 into pS4112 
downstream of the E1 genes (hTERT, Scerev §) 
pS4303 Insertion of prMin-RGC-Gal4-KRAB-IRES-I-Sce I-unit from 
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Plasmid Properties 
pS725 into pS4116 downstream of the E1 genes (CMV, Scefw §) 
pS4315 Insertion of prMin-RGC-Gal4-KRAB-IRES-I-Sce I-unit from 
pS725 into pS4098 downstream of the E1 genes (CMV, Scerev §) 
pS4356 Insertion of prMin-RGC-Gal4-KRAB-IRES-EGFP-unit from 
pS3208 into pS4129 downstream of the E1 genes (hTERT, Scefw 
§) 
pS4372 Insertion of prMin-RGC-Gal4-KRAB-IRES-EGFP-unit from 
pS3208into pS4116 downstream of the E1 genes (hTERT, Scerev 
§) 
pS4416 Insertion of IRES-EGFP from pIRES2-EGFP into DS122-
prMin-RGC 
pS4532 Insertion of prMin-RGC-I-Sce I-unit from pS4416 into pS4098 
downstream of the E1 genes (hTERT, Scerev §) 
pS4565 Insertion of prMin-RGC-I-Sce I-unit from pS4416 into pS4112 
downstream of the E1 genes (hTERT, Scerev §) 
pS4865 Integration of mut-Mcl-1 in pQCXIP 
pS4871 Integration of wt-Mcl-1 in pQCXIP 
pS5060 Integration of mut-Mcl-1 in pQCXIN 
pS5070 Integration of wt-Mcl-1 in pQCXIN 
Ad4226 Integration of E1 and prMin-RGC region of pS4226 in pAdHM4 
Ad4532 Integration of E1 and prMin-RGC region of pS4532 in pAdHM4 
Ad4233 Integration of E1 and prMin-RGC region of pS4233 in pAdHM4 
Ad4565 Integration of E1 and prMin-RGC region of pS4565 in pAdHM4 
Ad4303 Integration of E1 and prMin-RGC region of pS4303 in pAdHM4 
Ad4356 Integration of E1 and prMin-RGC region of pS4356 in pAdHM4 
Ad4315 Integration of E1 and prMin-RGC region of pS4315 in pAdHM4 
Ad4372 Integration of E1 and prMin-RGC region of pS4372 in pAdHM4 
pS5408 EGFP in pQCXIP 
pS5477 shRNA against Bax (shBax_1) in NW1187 
pS5483 shRNA against Bax (shBax_2) in NW1187 
pS5486 shRNA against Bax (shBax_3) in NW1187 
pS5490 shRNA against Bak (shBak_1) in NW1187 
pS5493 shRNA against Bak (shBak_2) in NW1187 
pS5498 shRNA against Bak (shBak_3) in NW1187 
pS5504 Fragment of the human Bak-gene in psiCHECK-2 
pS5510 Fragment of the human Bax-gene in psiCHECK-2 
pS5600 EGFP in pQCXIN 
pS5653 shRNAs against Bax (shBax_1) and against Bak (shBak_2) in 
NW1187 
pS5670 shRNAs against Bak (shBax_2) and against Bax (shBax_2) in 
NW1187 
pS5685 Puromycin resistance gene (PCR product from pQCXIP) in 
pBluescript 
pS5701 Neomycin resistance gene (PCR product from pQCXIN) in 
pBluescript 
pS5757 Puromycin resistance gene from pQCXIP in NW4739 
pS5779 Neomycin resistance gene from pQCXIN in NW4739 
pS5839 U6-promoter controlling shRNA against Bax (shBax_1) in 
pS5757 
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Plasmid Properties 
pS5848 U6-promoter controlling shRNA against Bak (shBax_2) in 
pS5757 
pS5862 U6-promoter controlling shRNA against Bax (shBax_1) and Bak 
(shBak_2) in pS5757 
pS5926 U6-promoter controlling shRNA against EGFP in pS5757 
 
§
 Scefw: TAGGGATAACAGGGTAAT; Scerev: ATTACCCTGTTATCCCTA 
 
 
 
5.1.5 Adenoviruses 
 
5.1.5.1 Provided Adenoviral vectors 
 
Ad-
(Plasmid) 
Supplier/ 
Source 
Properties 
Ad-
p53Sensor 
Florian Kühnel Conditionally replicating human Adenovirus 
type 5 selective for cells with transcriptionally 
inactive p53 (from plasmid stock) 
wt-Ad5 Florian Kühnel Wild type human Adenovirus type 5 (from 
infectious particles) 
ONYX-015 Frank 
McCormick 
Conditionally replicating human Adenovirus 
type 5 with deleted E1B region from ONYX 
Pharmaceuticals, Inc. (from infectious 
particles) 
 
5.1.5.2 Constructed Adenoviral vectors 
 
Plasmid Properties 
Ad4226 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-I-Sce I cassette (E1A controlled by CMV230-promoter) 
Ad4532 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-EGFP cassette (E1A controlled by CMV230-promoter) 
Ad4233 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-I-Sce I cassette (E1A controlled by hTERT-promoter) 
Ad4565 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-EGFP cassette (E1A controlled by hTERT-promoter) 
Ad4303 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-Gal4-KRAB-IRES-I-Sce I cassette (E1A controlled by 
CMV230-promoter) 
Ad4356 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-Gal4-KRAB-IRES-EGFP cassette (E1A controlled by 
CMV230-promoter) 
Ad4315 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-Gal4-KRAB-IRES-I-Sce I cassette (E1A controlled by 
hTERT-promoter) 
Ad4372 Replicative human Adenovirus type 5 regulated by a prMin-
RGC-Gal4-KRAB-IRES-EGFP cassette (E1A controlled by 
hTERT-promoter) 
  
5. MATERIALS AND METHODS  29 
   
5.1.6 VSV 
 
VSV-
(Plasmid) 
Source Description 
wt-VSV 
Indiana 
Mahtab 
Nourbakhsh, 
MHH, 
Hannover 
Wild type Vesicular Stomatitis Virus Indiana 
serotype (from infectious particles) 
AV1 Oliver Ebert, 
TU Munich 
Attenuated VSV with mutant matrix protein 
(M51R) 
 
5.1.7 Oligonucleotides 
 
All oligonucleotides were purchased from Eurofins MWG GmbH.  
 
Name Sequence in 5’-3’-
direction 
Description 
SceHis_
3 
AGAAGCTTGCCACCATGGGA
TCAAGATCGCCAAAAAAG 
Insertion of a HindIII-cleavage site and 
a Kozak-site (italic) 
SceHis_
4 
AAGGATCCTTAATGGTGATG
GTGATGATGACTTCCTTTCA
GGAAAGTTTCGGAGGAGATA
GTG 
Insertion of a BamHI- cleavage site and 
a His6-tag (italic) 
Sce-
Primer_
5 
ATAGGCCTAAAAACTAGTGC
TAGCTATTCCATGGGATCAA
GATCGCCAAAAAAGAAGAGA
AAGG 
Insertion of cleavage sites for Stu I, Spe 
I, Nhe I and Nco I 
Sce-
Primer_
6 
CCAAGCTTCTGCAGGTCGAC
TCTAGAGGATCC 
Insertion of a BamHI- cleavage site 
SceEGF
P_fw 
ACAAGCTTGGATCCGATATC
TAGGGATAACAGGGTAATAG
CCACCATGGTGAGCAAGGGC
GAGG 
Insertion of cleavage sites for HindIII, 
BamHI, EcoRV, I-Sce I and Nco I and a 
Kozak-site (italic) 
SceEGF
P_rev 
AAAGATCTGTCGACACGCGT
CCTCTCTGTCTCGGGTAAGA
TACATTGATGAGTTTGGACA
AACC 
Insertion of cleavage sites for Bgl II, Sal 
I, and Mlu I 
bcl-
x_fwd 
AAGCTAGCAATGTCTCAGAG
CAACCGGGAGC 
Insertion of a Nhe I cleavage site 
bcl-
x_rev 
TTAGATCTGGATGGTCAGTG
TCTGGTCATTTCC 
Insertion of a EcoRI cleavage site 
sceE1B_
fw1 
AAGAATTCATGAAATAAAGC
AATGAATGCACACCAACAAC
ATCATATGGTAGGGATAACA
GG 
Insertion of a start codon (ATG) in all 
three reading frames and part of a I-Sce 
I-recognition site 
SceE1B
_rev1 
TTGCGGCCGCATTACCCTGT
TATCCCTACCATATGATGTT
GTTGG 
Insertion of an I-Sce I-recognition site 
sceE1B_
fw2 
AAGAATTCATGAAATAAAGC
AATGAATGCACACCAACAAC
ATCATATGGATTACCCTGTT
ATCC 
Insertion of a start codon (ATG) in all 
three reading frames and part of a I-Sce 
I-recognition site 
sceE1B_
rev2 
TTGCGGCCGCTAGGGATAAC
AGGGTAATCCATATGATGTT
GTTGG 
Insertion of an I-Sce I-recognition site 
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Name Sequence in 5’-3’-
direction 
Description 
sceCMV
230_fw 
AAGGATCACAGGGTAATCCA
TGGTGATGCGGTTTTGGCAG
TACATCAATGG 
Insertion of a Nco I-cleavage site 
sceCMV
230_rev 
TTGCTAGCTCTAGAATTACC
CTGTTATCCCTATAGCGGAT
CTGACGGTTCACTAAACCAG
C 
Insertion of an I-Sce I-recognition site 
scehTE
RT_fw 
AAGCGCCAGGGTACTCCATG
GATGCTGCGCTGTCGGGGCC
AGG 
Insertion of a Nhe I-cleavage site 
scehTE
RT_rev 
TTGCTAGCTCTAGAATTACC
CTGTTATCCCTACGAGCCCG
CTGCCTGAAACTCGC 
Insertion of an I-Sce I-recognition site 
Mcl_fw AAAAGCTTAAGGATCCATGT
TTGGCCTCAAAAGAAACGCG 
Insertion of cleavage sites for HindIII 
and BamHI, 
Mcl-rev TTTCTAGACCGAATTCCTAT
CTTATTAGATATGCCAAACC
AGCTCC 
Insertion of cleavage sites for Xba I and 
EcoRI 
E1A_cut
control_
rev 
CGAGGAGGCGGTTTCGCAGA
TT 
Forward primer to generate PCR 
product specific for I-Sce I dependent 
religation 
E1B_cut
control_
fw 
CTAAGATATTGCTTGAGCCC
GAGAGC 
Reverse primer to generate PCR product 
specific for I-Sce I dependent religation 
mir30-
Xba 
AAATCTAGAGAATTCCGAGG
CAGTAGGCA 
Primer providing a Xba I-site and 5’-
flanking sequnence for shRNAs 
mir30-
Xho 
TTCTCGAGAAGGTATATTGC
TGTTGACAGTGAGCG 
Primer providing a Xho I-site and 3’-
flanking sequnence for shRNAs 
 
Sequencing primer 
 
Name Sequence in 5’-3’-direction 
Seq-Luc-primer GGATAGAATGGCGCCGGG 
Rvprimer3 CTAGCAAAATAGGCTGTCCC 
Rvprimer4 GACGATAGTCATGCCCCGCG 
SeqPrim_E1B_end TGCTGGATGTGACCGAGG 
seq_E1Astart_rev CAAAGCGAACACATAATATCTGGGTCCCCC 
E1Bterm_fw TTAGGAACCAGCCTGTGATGCTGG 
ProtIX_rev TAGTAGAGTTTGCGGGCAGGACG 
SeqPrimpQCXI_fw CCATCCACGCTGTTTTGACC 
U6 primer 1.2 GGACTATCATATGCTTACCGTAACTTG 
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5.1.8 Antibodies 
 
5.1.8.1 Primary antibodies 
 
Antibody Antigen Origin Dilution Supplier 
sc-1615 Actin Goat, polyclonal 1:1000 Santa Cruz 
Biotechnology 
sc-430 Ad2-E1A Rabbit, polyclonal 1:1000 Santa Cruz 
Biotechnology 
Y164 
(ab32371) 
Bak Rabbit, polyclonal 1:500 Abcam plc 
E63 
(ab32503) 
Bax Rabbit, polyclonal 1:1000 Abcam plc 
N-19 (sc-
492) 
Bcl-2 Rabbit, polyclonal 1:100 Santa Cruz 
Biotechnology 
L-19 (sc-
1041) 
Bcl-XS/L Rabbit, polyclonal 1:1000 Santa Cruz 
Biotechnology 
AF680 Bid Goat, polyclonal 1:800 R&D Systems 
2819 Bim Rabbit, polyclonal 1:1000 Cell Signaling 
Technology 
BP7052 eIF2alpha 
(pSer52) 
Rabbit, polyclonal 1:1000 Acris Antibodies 
GmbH 
sc-577 Gal4-DNA-
binding domain 
Rabbit, polyclonal 1:2000 Santa Cruz 
Biotechnology 
12CA5 HA-tag Mouse, 
monoclonal 
1:1000 Roche Applied Science 
A190-
108A 
HA-tag Rabbit, polyclonal 1:2000 Bethyl Laboratories, 
Inc. 
AAP-240 Mcl-1 Rabbit, polyclonal 1:7000 Stressgen 
sc-372 NFkappaB (p65) Rabbit, polyclonal 1:1000 Santa Cruz 
Biotechnology 
IMG-
349A 
NOXA Mouse, 
monoclonal 
1:500 Imgenex 
4976 PUMA Rabbit, polyclonal 1:1000 Cell Signaling 
Technology 
53015.11 PARP Rat, polyclonal 1:1500 R&D Systems (Bettina) 
12-6766 PARP Rabbit, polyclonal 1:600 eBioscience 
AB-6 
OP43 
p53 Mouse, 
monoclonal 
1:500 Calbiochem 
632375 rGFP Mouse, 
monoclonal 
1:4000 BD Living Colors 
A190-
130A 
VSV-G Goat, polyclonal 1:5000 
1:100 (IHC) 
Bethyl Laboratories 
Inc. 
2042 XIAP Rabbit, polyclonal 1:1000 Cell Signaling 
Technology 
 
5.1.8.2 Secondary antibodies 
 
Antibody Antigen Origin, properties Dilution Supplier 
AQ127P Mouse goat, HRP-coupled 1:10.000 Chemicon Intl. 
7074 Rabbit goat, HRP-coupled 1:10.000 Cell Signaling 
Technology 
sc-2056 Goat donkey, HRP-
coupled 
1:10.000 Santa Cruz 
Biotechnology 
705-066-
147 
Goat donkey, biotin-
coupled 
1:200 (IHC) The Jackson Laboratory 
 Rat donkey, HRP-
coupled 
1:10.000 Dianova 
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5.1.9 Chemicals 
 
All experiments were performed in S1 or S2 laboratories at Hannover Medical 
School equipped for molecular biological work. Displayed exclusively are 
chemical substances that might have influenced the outcome or the form of the 
experiments. 
 
Substance Supplier 
5-Fluorouracil Hannover Medical School 
5x Bradford-solution Bio-Rad Laboratories GmbH 
Ampicillin Sigma-Aldrich 
ATP (for DNA ligation) Sigma-Aldrich 
Carbenicillin Serva Electrophoresis GmbH 
Chloroquine Sigma-Aldrich 
4’,6-Diamidino-2-
phenylindole 
dihydrochloride (DAPI) 
Sigma-Aldrich 
Doxorubicin Hannover Medical School 
Kanamycin Sigma-Aldrich 
Lipofectamin2000 Invitrogen Corp. 
MG132 Calbiochem 
Mowiol Roth 
Neomycin Calbiochem 
10x PBS Invitrogen Corp. 
Polyethylenimine (25 kD) Polysciences Europe GmbH 
Puromycin Sigma-Aldrich 
To-Pro3 Invitrogen Corp. 
zVAD-fmk Calbiochem 
 
5.1.10 Molecular weight standards 
 
Name Application Supplier Cat. 
number 
1 kb plus DNA ladder DNA Invitrogen Corp. 10787-018 
peqGOLD Prestained 
Protein-Marker III 
Protein Peqlab Biotechnolgie 
GmbH 
27-1110 
 
5.1.11 Enzymes 
 
Antarctic phosphatase New England Biolabs GmbH 
DNA Polymerase I, Klenow fragment New England Biolabs GmbH 
Herculase Hotstart DNA Polymerase Stratagene Europe 
Lysozyme Sigma-Aldrich Chemie GmbH 
Proteinase K Roche Diagnostics GmbH 
Restriction endonucleases New England Biolabs GmbH 
Reverse Transcriptase Qiagen GmbH 
RNase Boehringer 
Streptavidine-HRP Zymed Laboratories 
T4-DNA Ligase New England Biolabs GmbH 
T4-Polynucleotide kinase New England Biolabs GmbH 
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5.1.12 Kits 
 
Qiagen Endofree Plasmid Midi/Maxi Kit Qiagen GmbH 
QIAquick Nucleotide Removal Kit Qiagen GmbH 
QIAquick Gel Extraction Kit Qiagen GmbH 
QIAquick PCR Purification Kit Qiagen GmbH 
Qiagen RNeasy Kit Qiagen GmbH 
ECL detection Kit GE Healthcare Europe GmbH 
Adeno-X rapid titer Kit Clontech 
Vivapure AdenoPACK 20 Sartorius AG 
AEC Histostain Plus Broad Spectrum Kit  Zymed Laboratories,  
In Situ Cell Death Detection Kit, POD  Roche Diagnostics GmbH 
Caspase-3 Activity Assay Kit Clontech 
 
5.1.13 Devices 
 
Fluorometer Biotek Instruments GmbH 
Photometer Biotek Instruments GmbH 
Lumat (Luminometer) Berthold 
HM 500 OM Cryostat Microm 
Zeiss LSM 510 Meta scan head on ZEISS  Carl-Zeiss MicroImaging  
Axiovert 200M equipped with an oil immersion  
objective lense 63 × /1.4, zoom factor 2.0 
Axiovision software Carl-Zeiss MicroImaging 
Zeiss LSM Image Browser 4.2 Carl-Zeiss MicroImaging 
QWinV3 software Leica 
GraphPad Prism 3.02 GraphPad Software Inc. 
 
5.1.14 Media and buffers 
 
For cell culture 
 
Storage medium for liquid nitrogen 
80 % DMEM + 10 % FCS, 10 % DMSO, 10 % FCS; sterile filtration 
 
For culture of bacteria 
 
LB medium: 10 g bactotryptone, 5 g yeast extract and 10 g NaCl solved in water 
adjusted 1 l and autoclaved. The medium is supplemented with antibiotics prior 
usage. Storage at room temperature. 
 
Agar plates: LB medium containing 1.5 % agar select was autoclaved, chilled to ~ 
60°C and supplemented with antibiotics. The final mix was applied to agar dishes 
and chilled until solidified. Storage at 4°C. 
 
SOC medium: 2 g tryptone, 0.5 g yeast extract, 0.05 g NaCl, 1 ml 1 M MgCl2, 1 
ml 1 M MgSO4 and 0.4 g glucose are filled up with water up to 100 ml sterilely 
filtered. Storage at -20°C. 
 
 
 
5. MATERIALS AND METHODS  34 
   
Buffers 
 
1 M TRIS pH 6.8 1 M TRIS-HCl pH 6.8 
 0.4 % SDS 
  
1.5 M TRIS pH 8.8 1.5 M TRIS-HCl pH 8.8 
 0.4 % SDS 
 
1x TAE 40 mM TRIS-HCl pH 8.5 
 1 mM EDTA 
 40 mM acetic acid 
 
2x BBS pH 6.95 280 mM NaCl 
 50 mM BES 
 1.5 mM Na2HPO4 x (2H2O) 
pH 6.95 (optimization by transfection experiments 
necessary) 
sterile filtration 
 
2x storage buffer (Adenovirus) 10 mM TRIS-HCl pH 8.0 
 100 mM NaCl 
 0.1 % BSA 
 50 % Glycerol 
 sterile filtration 
 
5x extraction buffer (luciferase) 125 mM TRIS-HCl pH 7.8 (H3PO4) 
 10 mM EDTA 
 50 % glycerine 
 5 % Triton-X-100 
 
5x SDS protein load 310 mM TRIS-HCl pH 6.8 
 250 mM DTT 
 20 % glycerine 
 2 % SDS 
 0.2 % bromophenol blue 
 
10x DNA loading buffer 20 % Ficoll 400 
100 mM EDTA pH 8.0 
1 % SDS 
bromophenol blue 
 
10x SDS buffer 250 mM TRIS HCl pH 8.3 
 1.92 M glycerine 
 1 % SDS 
 
ATP stock for luciferase assay 100 mM ATP 
 200 mM TRIS 
 storage at -20°C 
 
β-Galactosidase reaction buffer 60 mM Na2HPO4 
 39 mM NaH2PO4 
 10 mM KCl 
 1 mM MgSO4 
  
 prior use: 
 2 mM DTT 
5. MATERIALS AND METHODS  35 
   
 1 mg/ml ONPG 
 
Cesium chloride gradient density 1.2 g/ml (50 ml) 
  13.25 g CsCl 
  0.5 ml 1 M TRIS-HCl pH 7.5 
 density 1.4 g/ml (50 ml) 
  26.75 g CsCl 
  0.5 ml 1 M TRIS-HCl pH 7.5 
 
Dialysis buffer 10 mM TRIS-HCl pH 8.0 
 1 mM MgCl2 
 140 mM NaCl 
 
Luciferine 25 mM D-luciferine sodium salt in water 
 storage at -20°C 
  
Luciferase reaction buffer 25 mM glyceryl glycine 
 15 mM MgSO4 
 50 mM ATP prior use 
 
RIPA-buffer 60 ml 10x PBS 
 6 ml Igepal 
 3 g deoxycholic acid-sodium salt 
 0.6 g SDS 
 final volume adjusted 600 ml 
 
Before use: 5 µl protease inhibitor mix 
(Calbiochem) per 1 ml 
 
STET buffer 50 mM TRIS-HCl pH 8.0 
 50 mM EDTA 
 8 % sucrose 
 0.5 % Triton X-100 
 
TAIL buffer 50 mM TRIS-HCl pH 8.0 
 100 mM EDTA pH 8.0 
 5100 mM NaCl 
 1 % SDS 
 20 µg/ml proteinase K added before use 
 
TE 10 mM TRIS-HCl pH 8.0 
 1 mM EDTA pH 8.0 
 
TBS-Tween 20 mM Tris-HCl pH 7.6  
 150 mM NaCl 
 0.3 % Tween 20 
 
Western blot transfer buffer 40 mM glycine 
 50 mM TRIS-HCl pH 8.3 
 1 mM SDS 
 1 l methanol 
 final volume adjusted 5 l  
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5.2 Cell biological methods 
 
5.2.1 Cell culture techniques 
 
Cell culture was performed according to modern guidelines for S1 and S2 safety 
levels. Regularly, contaminations with mycoplasma species were checked by a 
PCR protocol. 75 cm2 T-flasks, DMEM supplemented with FCS and an antibiotic 
Penicillin/Streptomycin were usually used to grow cells in incubators providing 
37°C and 5 % CO2. 
To propagate cells, medium was discarded and the cell layer washed with 1x PBS. 
Trypsinization (0.5 % Trypsin in 1x PBS) was performed to detach cells. Cells 
were resuspended in fresh medium and grown to 70 – 90 % confluence before next 
passage. 
To determine viable cell number per ml medium hemocytometer was used. Dead 
cells were excluded by Trypan blue staining. 
Cells were stored in liquid nitrogen resuspended in freezing medium consisting of 
80 % growth medium, 10 % DMSO and additional 10 % FCS. To prevent 
contamination with microorganisms the solution was sterilely filtered.  
Culturing cells from nitrogen storage started with a quick thaw. Washing with 
growth medium eliminated residual DMSO traces. Cells were resuspended in fresh 
medium that was refreshed after cell attachment to remove cellular debris. 
 
5.2.2 Transfection of cell lines 
 
5.2.2.1 Lipofectamin2000 
 
Cells were propageted in a 60 mm plate to achieve a nearly confluent layer (~ 90 
%). Immediately before transfection medium was replaced by 2 ml Optimem 
(serum-free medium). 8 µg DNA were resolved in 500 µl Optimem as was the 
transfection reagent (16 µl; Lipofectamine2000). Both solution were combined and 
mixed gently. About 20 min at RT the mix was applied to the cells and incubated 
at 37°C for 4 h. Transfected cells were treated according to the manufacturer’s 
protocol. 
 
5.2.2.2 Calciumphosphate 
 
About 0.9x 106 cells were seeded to 60 mm plates and grown to about 70 % 
confluence. For transfection 5 µg of DNA were mixed with 150 µl 250 mM CaCl2 
and 150 µl 2x BBS and spun down according to Chen and Okayama. After 
incubation an RT for 15 – 25 min the mixture was applied to cells with 2 ml 
freshly provided growth medium by slightly shaking the plate. Fresh medium was 
provided 12 -15 h after start of the transfection. Cells were monitored and treated 
due to the experimental setup. 
 
5.2.2.3 Polyethylenimine (PEI) 
 
Cells were seeded in 60 mm plates to achieve about 90 % confluence 
(approximately 1.2x 106 cells). Before transfecting target cells medium without 
FCS had to be applied. 5 µg DNA and 10 µl of a 10 mg/ml PEI solution were 
separately resolved in 200 µl serum-free medium. Both solutions were mixed and 
incubated at RT for additional 25 min to form complexes. 400 µl of the 
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transfection mix were added to the cells and incubated for 4 h. Then, the 
transfection medium was discarded and replaced by fresh growth medium. Cells 
were monitored and harvested due to the experimental setup. 
 
5.2.3 Microscopical methods 
 
5.2.3.1 Fluorescence microscopy 
 
TUNEL and nuclear staining with DAPI were analyzed at the fluorescence 
microscope Leica DM4000B. Merged images of both signals were created by 
Leica QWinV3 software (blue – DAPI staining; green – TUNEL staining). 
 
5.2.3.2 Confocal Laser Scanning Microscope (CLSM) 
 
The intracellular distribution of the fusion protein YFP-LC3 that was stably 
expressed in A549, HepG2 and Huh-7 cell lines was analyzed by confocal laser 
scanning microscopy at the Laser Microscopy Facility at Hannover Medical 
School with a Zeiss LSM 510 Meta scan head on ZEISS Axiovert 200M equipped 
with an oil immersion objective lense 63 × /1.4. Generally a zoom factor of 2.0 
was applied to record fluorescence images. Later on these images were processed 
with software from Carl-Zeiss MicroImaging (Axiovision software, Zeiss LSM 
Image Browser 4.2). 
 
1 – 2x 105 cells were grown on cover glasses in 6 well plates over night. For 
experiments medium was refreshed (1 ml) and 100 µl of virus or chloroquine 
solution was added. After incubation of indicated times cover glasses were rinsed 
with 1x PBS and fixed in 4 % paraformaldehyde for 10 min at RT. After an 
additional washing step cover glasses were tissue dried and cells were stained with 
about 60 µl of 1 µM To-Pro3 solution (nuclear staining). Glasses were incubated 
(10 min, RT) in a humid and dark chamber to prevent fading of the dye. After a 
washing step (1x PBS) cover glasses were dried and put on a glass slides prepared 
with mounting medium (Mowiol). Incubation at RT (30 min) and 4°C (over night) 
provided samples appropriate for CLSM analysis. 
 
Before recording microscopic parameters for adequate measurement range were 
set by positive and negative control samples. This preparation was performed 
before each experiment but the established configuration was never changed 
within a single experimental setup. Pictures were recorded as single slices on a 
certain cellular level and as scanning picture series (up to 15 slices per cell). 
Resulting files were processed with the above mentioned software to present YFP, 
To-Pro3 signals and merged images of both signals. 
 
5.2.4 Tissue staining 
 
To test the intratumoral effect of applied therapies, tumors were analyzed by tissue 
staining. Preparation of tumor slices, Haematoxylin/Eosin (HE) and VSV-G 
staining were performed by Meriame Nasiri and Gisela Weier at Hannover 
Medical School. 
For this reason A549 tumors were grown on nude mice, treated like indicated and 
finally explanted. To perform HE staining and staining against VSV-glycoprotein 
protein tumors were incubated in 4 % paraformaldehyde in PBS over night (4°C) 
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and embedded in paraffin to prepare 5 µm sections from tumor tissue. Resulting 
sections were subjected to specific staining that is described in the following two 
chapters. 
 
5.2.4.1 Haematoxylin/Eosin (HE) 
 
A549 tumors in nude mice were treated for several weeks and subsequently 
explanted. Paraffin tumor sections were dried, deparaffinized and, rehydrated. 
Haematoxylin staining was performed for 30 – 90 s. After washing with water 
samples were Eosin stained and dehydrated. Samples were covered with glasses 
using Entelan. Samples were analyzed with a bright light microscope. 
 
5.2.4.2 Immune histochemistry 
 
Distribution of VSV within A549 tumors was analyzed by detecting the 
glycoprotein of VSV (VSV-G) that is located in the cell membrane of infected 
cells. Tumor sections were stained with goat-anti VSV-G antibody (1:100), 
biotinylated donkey-anti-goat antibody (1:200) and streptavidine-HRP. Using the 
AEC Histostain Plus Broad Spectrum Kit (Zymed Laboratories, San Francisco, 
CA) infected cells were visualized. Samples were monitored with a bright field 
microscope. 
 
5.2.4.3 TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) 
staining 
 
A549 tumors in nude mice were treated for up to 5 days and subsequently 
explanted. Paraffin tumor sections were dried and deparaffinized. TUNEL assay 
was performed according to the manufacturer’s guidelines (In Situ Cell Death 
Detection Kit, POD Roche Diagnostics GmbH). Cellular peroxidases were blocked 
by incubating slides in 3 % H2O2 (in methanol) for 10 min. Washing twice in 
water preceded an incubation in 0.01 M citrate buffer (pH 6.0) for 5 min at 750 W 
and additional 15 min at 150 W in a microwave. After chilling the slides for 10 
min at RT and washing twice in 1x PBS the tissue was permeabilized with 
proteinase K (20 µg/ml in 1x PBS) for 30 min. Proteinase K was removed by 
washing twice in 1x PBS. Then, samples were fixed in 4 % paraformaldehyde for 
1 h and washed again. Before the final TUNEL reaction samples were incubated in 
0.1 % sodium citrate and 0.1 % Triton-X-100 for 30 min and washed twice in 1x 
PBS. Freshly prepared TUNEL reaction mix to stain DNA double strand breaks 
was applied to the samples for 1.5 h and removed by washing with 1x PBS. 
Finally, nuclei were counterstained with DAPI and covered with glasses in 
mounting medium (Mowiol). Images were recorded on a fluorescence microscope. 
 
 
 
5.3 Protein biochemical methods 
 
5.3.1 Preparation of protein extracts from cell culture 
 
Cell layers were controlled by bright field microscopy. After washing the cell layer 
twice with 1x PBS cells were harvested in RIPA buffer containing a pan-protease 
inhibitor cocktail and incubated on ice for 30 min. Cell debris was pelleted in a 
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table top centrifuge (10,000 g, 10 min, 4°C) and supernatants were transferred to 
fresh tubes. 
 
5.3.2 Determination of protein concentration 
 
Dilutions of protein containing 0 to 6 mg/ml BSA (NEB) were applied as 
standards (in the same buffer as samples are harvested). 
The purchased Bradford solution was diluted 1:4 in water. Fresh tubes were 
provided with 198 µl water and 2 µl of sample/standard. 800 µl of diluted 
Bradford solution was added to each protein dilution and mixtures were shaken 
slightly. Per sample 200 µl of the final mixture were applied to a flat bottomed 96 
well plate. Absorbance was measured from duplicates at 595 nm and 
concentrations were calculated by Gen5 software (Biotek Instruments GmbH). 
 
5.3.3 SDS-PAGE and western blot analysis 
 
Separation of protein solutions was performed by denaturing SDS-polyacrylamid 
gel electrophoresis. Composition of the resolving gels (10 or 12.5 %) and the 
stacking gel is shown in the tables below. 
 
Resolving gels 
% Acrylamid/ 
Bisacrylamid 
1.5 M TRIS pH 8.8 
+ 0.4 % SDS 
H2O 10 % 
APS 
TEMED 
10.0 8 ml 6 ml 9.75 ml 240 µl 10 µl 
12.5 10 ml 6 ml 7.75 ml 240 µl 10 µl 
 
Stacking gel 
 Acrylamid/ 
Bisacrylamid 
1 M TRIS pH 6.8 
+ 0.4 % SDS 
H2O 10 % 
APS 
TEMED 
 1.65 ml 2.5 ml 5.85 ml  50 µl 10 µl 
 
10 – 100 µg protein were separated using a Biometra apparatus. Subsequently, 
proteins were transferred to a HyBond N-membrane (Millipore, Eschborn, 
Germany) by electroblotting. Membranes were blocked in TBS-Tween containing 
5 % milk and subjected to immunostaining. Antibodies were diluted in TBS-
Tween containing 5 % milk and applied to the blocked membrane over night (4°C) 
or for 1 h (RT). Membranes were washed in TBS-Tween six times for 10 min and 
incubated with the secondary antibody solution (in TBS-Tween) for 1 h. After 
washing in TBS-Tween (6x 10 min) membrane were developed applying the 
enhanced chemiluminescence detection system (ECL) according to the 
manufacturer’s protocol (Amersham, GE Healthcare Europe GmbH). 
 
5.3.4 Luciferase assays 
 
5.3.4.1 Firefly 
 
Transfected cells were incubated in growth medium for a certain time, then 
washed twice with 1x PBS. 5x Extraction buffer was freshly prepared and 350 µl 
were applied to the rinsed cell layer. After 10 min incubation at RT lysed cells 
were transferred to a fresh tube and centrifuged (16,000 g, 5 min, 4°C) to separate 
cell debris. Supernatant was applied to a fresh tube and stored at -20°C. 
5. MATERIALS AND METHODS  40 
   
 
Measurement of luciferase activity was performed usinga Lumat apparatus. For 
this purpose 300 µl of freshly prepared reaction buffer were mixed with 50 µl 
harvested cell lysat in measurement tubes and luciferine solution was applied. Per 
sample two measurements were carried out. 
 
5.3.4.2 Dual luciferase reporter system 
 
Promega’s psiCHECK-2-system allows analysis of shRNA efficiencies and 
simultaneous normalization of transfection efficiencies by expression of two 
different luciferases. The 3’-UTR of Renilla luciferase contains a MCS for 
integration of shRNA target gene sequences of choice. Firefly luciferase is 
expressed constitutively in an unaffected manner to allow for normalization of 
Renilla luciferase expression. 
 
Target gene sequences were generated by PCR from cDNA of A549 and inserted 
in psiCHECK-2 by Xho I and Not I cleavage. Plasmids coding for specific shRNA 
sequences controlled by a U6-promoter and the psiCHECK-2 vectors were co-
transfected in HepG2 cells. 48 h after transfection cells were lysed in freshly 
prepared extraction buffer and measurement of activities of both luciferases were 
performed according to the manufacturer’s protocols. Comparison of the 
normalized Renilla luciferase activities of specific shRNAs against a non-target 
shRNA revealed the down regulating potential of certain shRNA sequences. Based 
on these results shRNA sequences were selected for the generation of cell lines 
constitutively down regulating certain genes.  
  
5.3.5 β-Galactosidase assay 
 
To normalize transfection efficiencies plasmids coding for lacZ gene were co-
transfected. Activity of the β-galactosidase enzyme was analyzed by the ONPG 
assay. 20 mg ONPG (the substrate of β-galactosidase) was mixed with 20 ml β-
Galactosidase reaction buffer and 40 µl 1 M DTT. 10 µl cell lysat were applied to a 96 
well plate and the final ONPG solution (150 µl) was added. The reaction was carried out 
at RT (high β-galactosidase activity) or at 37°C (low β-galactosidase activity). After 
stopping the conversion of ONPG to a yellow product by applying 75 µl of 1 M Na2CO3 
the absorption was measured at 405 nm in Biotek’s photometer and normalization was 
usually performed by Excel calculation. 
 
5.3.6 Caspase-3-activation assay 
 
Cell death by induction of apoptosis can be monitored by measuring the activity of 
the enzyme caspase-3 playing a decisive role in this pathway. Clontech’s Caspase-
3 Activity Assay was applied to all experiments described in this work. 
For this reason, cells were seeded in 60 mm plates and treated according to the 
experimental plan. Cells were harvested by cell scraper in medium, centrifuged 
(1,000 g, 2 min, 4°C) and washed with 1x PBS. Pelleted cells were lysed in about 
200 µl of the provided cell lysis buffer and incubated for 10 min on ice. Samples 
were shock frozen in liquid nitrogen and stored at -80 C. 
 
Cell debris was removed by centrifugation (20,000 g, 2 min, 4°C). Protein 
concentrations of the remaining supernatants were determined by Bradford assay. 
According to the manufacturer’s protocol caspase-3 activities of 7 µl of sample 
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were measured 20 and 80 min after applying an enzyme substrate (Ac-DVED-
AFC-substrate, 5 mM in DMSO) or an inhibitor (Ac-DEVD-CHO, 1.5 mM in 
DMSO). Fluorescence (502 nm) was measured at the fluorometer (Bioteck 
Instruments GmbH) and fluorescence units per µg protein and hour were 
calculated. 
 
 
 
5.4 Molecular biological methods 
 
5.4.1 DNA amplification and purification 
 
In this work different techniques were applied to purify DNA out according to 
requirements for amount and/or quality of the purified DNA and will be described 
in this chapter. The E. coli safety strains JM109 and XL1-blue were used to 
amplify plasmids. While XL1-blue cells were electroporated exclusively JM109 
bacteria were accessible as chemically competent preparations as well. 
 
5.4.1.1 Mini format 
 
DNA from agar plate colonies or pAdHM4 plasmid was usually extracted from 
bacteria by a specific preparation protocol (preventing use of resins to bind DNA). 
Transformed bacteria were grown 7 – 14 h in LB medium and centrifuged (3,000 
g, 2 min, 4 °C). Medium was discarded except residual 100 µl to resuspend cells 
by vigorous shaking. The suspension was mixed with 300 µl STET buffer + 300 
µg/ml lysozyme. To weaken bacterial cell walls by lysozymal digestion cells were 
incubated 2 min at RT prior to boiling at 95°C for 90 s. The supernatant of the 
following centrifugation (20,000 g, 20 min, 4°C) was mixed with 400 µl 2-
propanol and centrifuged (20,000 g, 15 min, 4°C) again to precipitate DNA. The 
resulting pellet was washed with 70 % ethanol and resuspended in 15 – 30 µl TE 
buffer. 
 
5.4.1.2 Midi/Maxi format 
 
For the preparation of highly purified DNA in midi or maxi format appropriate kits 
(Qiagen Endofree Plasmid Midi/Maxi Kit) from Qiagen GmbH were applied. The 
purification method is based on a modified alkaline lysis procedure and functions 
by binding of plasmid DNA to an anion exchange resin.  
 
5.4.1.3 Phenol-Chlorofrom extraction 
 
In certain cases large DNA plasmids (e. g. pAdHM4) were purified by phenol-
chloroform extraction as this preparation method minimizes the problem of DNA 
shearing in contrast to column based methods, e. g. purification kits described 
above. 
The DNA containing solution was adjusted to 100 µl by TE buffer and mixed with 
100 µl commercial phenol-chloroform solution from Roth (Roti-
Phenol/Chloroform). After vigorous shaking aqueous and phenolic phases were 
separated by centrifugation (20,000 g, 2 min, 4°C). The upper hydrophilic phase 
was transferred to a fresh tube and supplemented with 25 µl 10 M ammonium 
acetate and 400 µl 100 % ethanol. DNA was precipitated by incubation at -20°C 
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(30 min), adding glycogen and a final centrifugation (20,000 g, 15 min, 4°C). 
After washing the pellet with 70 % ethanol DNA was resuspended in an 
appropriated volume of TE buffer or 10 mM TRIS-HCl pH 8.0. 
 
5.4.2 DNA sequencing 
 
For sequencing DNA fragments commercial services of GATC Biotech AG, 
Konstanz and Eurofins MWG GmbH, Ebersberg were employed. 
 
5.4.3 Transformation 
 
5.4.3.1 Chemical Transformation 
 
To amplify DNA plasmids 80 µl chemically competent JM109 cells were 
incubated with up to 15 µl DNA solution (e. g. ligation mix) for 30 min on ice. 
Bacterial solution was heat-shocked at 42°C for 90 s and subsequently cooled on 
ice for 2 min. After resuspending cells in 100 µl SOC medium and culturing at 
37°C for 30 min bacteria were spread on an agar plate and cultured over night. 
Plasmids from arising colonies were monitored by restriction enzyme analysis. 
 
5.4.3.2 Electroporation 
 
To transform bacteria with large DNA plasmids a method termed electroporation 
was used. 40 µl of electro-competent JM109 or XL1-blue cells were mixed with 
up to 1.5 µl of DNA solution and applied to a chilled electroporation cuvette 
between to electrodes. Electroporation was performed at voltages of 1.7 – 1.8 kV 
in a specialized apparatus called electroporator (Bio-Rad E. coli pulser). 
Immediately after the voltage pulse up to 1 ml of SOC medium was added to the 
bacteria and transformed cells were incubated at 37°C for 30 min. After spreading 
on an agar plate bacteria were cultured over night and resulting colonies were 
analyzed for plasmid specimen. 
 
5.4.4 DNA recombination techniques 
 
To recombine different DNA fragments DNA was cleaved using restriction 
enzymes purchased from New England Biolabs, Inc. (NEB). If necessary, sticky 
DNA ends resulting from enzyme cleavage were blunted using Klenow fragment 
(NEB). Desired fragments were separated by agarose gel electrophoresis and 
purified using Qiagen’s Gel Extraction Kit. Appropriate DNA fragments were 
mixed and in vitro ligated by T4 DNA ligase (NEB). To prevent religation of DNA 
5’-ends cleaved vectors were dephosphorylated by Antarctic phosphatase (NEB) 
prior ligation. Subsequent transformation of successfully ligated plasmids resulted 
in transformed bacteria that were applied for DNA amplification. 
 
Constructed, purified or provided plasmids were analyzed by restriction enzyme 
cleavage. Resulting fragments were separated on agarose gels and compared to 1 
kb+ DNA standard to gain knowledge of the quality of analyzed plasmid sample. 
If the cleavage pattern was not applicable for analysis target DNA regions were 
sequenced. 
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5.4.5 PCR 
 
In this work the polymerase chain reaction was used to introduce cleavage sites for 
restriction enzymes, to extend hybridized oligonucleotides and to detect certain I-
Sce I-mediated DNA religation products. All three procedures are described 
below. 
 
5.4.5.1 Insertion of RE sites 
 
To introduce certain recognition sites for restriction enzymes oligonucleotides 
were designed comprising corresponding sequences. To estimate annealing 
temperatures (TM) the following formula was applied for primers > 20 bases: 
 
TM  = 58.9°C + 0.41x (GC) – 600x (length) 
 
  GC % of G or C nucleotides in the binding sequence 
  length number of nucleotides that bind to the template 
 
When RE sites were introduced usually two annealing temperatures had to be 
calculated (for partial and total annealing of the primers) and the PCR program 
consisted of two-parted. 
For the generation of UTR-modified genes proof-reading HotStart Herculase was 
used to minimize the rate of mutation. In some cases DMSO (1 – 5 %) and melting 
substances were necessary to generate the desired products. 
 
5.4.5.2 Generation of miR30 DNA fragments 
 
MiR30 short hairpin sequences (116 bp) were generated within a single 
polymerase chain reaction using Herculase Hotstart DNA Polymerase. Four 
primers were used, two constant and two specific for the desired shRNA sequence 
(figure 4). Depicted below are the composition of a 100 µl PCR mix and a 
schematic picture of the PCR principle: 
 
 concentration volume (µl) 
Herculase reaction buffer 10x 10 
DMSO 100 % 2 
dNTP 10 mM 4 
shPrimer forward 100 µM 1 
shPrimer reverse 100 µM 1 
mir30-Xba 100 µM 1 
mi30-Xho 100 µM 1 
Herculase enzyme 5 u/µl 1 
water  79 
 
5. MATERIALS AND METHODS  44 
   
 
Figure 4. Generation of functional shRNA molecules by PCR. Two primers providing 
flanking sequences and cleavage sites for cloning and two primers specific for every 
target RNA region were applied in a single PCR to generate a single shRNA molecule. 
 
 
The reaction program was three-parted: 
 
Temperature (°C) Time (s) Repeats 
95 600  
95 30 
55 30 
72 30 
 
5x 
95 30 
56 30 
72 30 
 
5x 
95 30 
60 30 
72 30 
 
30x 
72 600  
 
 
5.4.5.3 PCR-assisted detection of I-Sce I-cleavage products of the E1 region 
 
The activity of Adenovirus-encoded I-Sce I protein could be detected by a simple 
PCR method that exploits the efficient religation of a certain cleavage product by 
host cell DNA repair mechanisms. Briefly, a fragment of the Adenoviral genome 
spanning about 3,000 nucleotides is framed by two I-Sce I recognition sites. When 
cleaved the linear DNA could be religated at a certain position. This two-step-
event could be monitored by a PCR method. 
 
Target cells were infected with recombinant Adenoviruses and incubated for an 
indicated time. Cell layers were washed and lysed by TAIL buffer and DNA was 
prepared by 2-propanol precipitation and RNA digestion. 300 ng of the purified 
DNA were added to the PCR mixture with a total volume of 50 µl: 
 
 concentration volume (µl) 
Template (purified DNA) 50 ng/µl 6 
Primer E1A_cutcontrol_rev 10 µM 2.5 
Primer E1B_cutcontrol_fw 10 µM 2.5 
DMSO 100 % 2 
Taq-Master (Qiagen) 2x 25 
Water  12 
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The PCR program is depicted below: 
 
Temperature (°C) Time (s) Repeats 
95 600  
95 30 
55 30 
72 45 
 
35x 
72 600  
 
PCR products were analyzed in agarose gel and by DNA sequencing. 
 
5.4.6 DNA extraction from cell culture 
 
About 1x 106 PBS-washed cells were lysed in TAIL buffer and incubated at 56°C 
over night. Cell debris was removed by centrifugation (10,000 g, 10 min, 4°C). 
Supernatant was mixed with the same volume 2-propanol and centrifuged (20,000 
g, 15 min, 4°C) to precipitate DNA. After washing with 70 % ethanol DNA was 
resuspended in 25 µl TE buffer and RNA was digested for 1 h at 37 °C. The 
concentration of DNA was determined by photometric measurement.  
 
 
 
5.5 Virological techniques 
 
In the context of this work recombinant Adenoviruses and wild type Vesicular 
Stomatitis Virus were analyzed regarding their host cell interaction. For this 
purpose, stably expressing cell lines were created by the help of retro- or lentiviral 
gene transfer. Methods related to the virus-assisted generation of these cell lines 
are described in this chapter likewise. 
 
5.5.1 Adenovirus 
 
5.5.1.1 Cloning 
 
Construction of recombinant replicative Adenovirus vectors was based on an in 
vitro ligation method described by Mizuguchi and Kay 1998. To insert foreign 
DNA cassettes into an adenoviral DNA backbone two unique restriction sites (I-
Ceu I and PI-Sce I) were introduced in a vector – termed pAdHM4 (30.3 kb) – 
containing a complete E1, E3-deleted human Adenovirus type 5 genome. A 
pHM3-based shuttle plasmid providing the Adenoviral E1 region was used as 
construction platform for the development of DNA cassettes coding for regulative 
elements.  
The final recombinant E1-region was inserted in pAdHM4 according to Mizuguchi 
and Kay. Briefly, 2 µg shuttle plasmid and 3 µg of a DNA minipreparation of 
pAdHM4 were digested with I-Ceu I and PI-Sce I. Insert DNA was gel-purified 
and concentrated by QIAquick Gel Extraction Kit. To prevent shearing of the large 
pAdHM4 DNA it was exclusively purified by phenol-chloroform extraction. In 
vitro ligation was performed over night at 16°C and 1.5 µl of the ligation mix was 
used to transform XL1-blue cells by electroporation. After selection of positive 
clones by restriction analysis DNA was used to transform electro-competent 
JM109 cells yielding a higher amount of DNA than XL1-blue.  
5. MATERIALS AND METHODS  46 
   
 
5.5.1.2 Production and amplification 
 
Final pAdHM4 based plasmids coding for recombinant Adenoviral genomes were 
Pac I cleaved to generate linear DNA that could be utilized as transcription and 
replication template. About 9x 105 HEK 293 cells were seeded in a 60 mm plate 
and transfected with the linearized vector. 5 days after transfection cells were 
scraped in medium and viral particles were released by three freeze-thaw-cycles 
(in liquid nitrogen/37°C). Cell debris was removed by centrifugation and the 
remaining supernatant was added to a fresh layer of HEK 293 cells. About 50 h 
later cells were harvested again as described above. Successful virus production 
could be monitored by cytopathic effect and rapid turning of the medium’s color to 
yellow. Scaling up the number of infected cells increased the produced virus 
amount.  
Two different purification methods were applicable for Adenoviral particles: 
ultracentrifugation and a column-based procedure. The first required about 40 
confluent 75 cm2-flasks of infected HEK 293 cells, the latter 2 flasks. 
 
Adenovirus purification by ultracentrifugation 
 
About 40 75 cm2-flasks of infected HEK 293 cells were infected with an 
Adenovirus vector and harvested about 60 h later when a clear CPE occurred. 
Cells were separated by centrifugation (500 g, 5 min, 4°C) and resuspended in 
dialysis buffer. To free viral particles from cell nuclei cells were freeze-thawed 
three times. The lysat was cleared by centrifugation (2,000 g, 5 min, 4°C) and the 
pelleted cells subjected to an additional freeze-thaw cycle. After centrifugation 
both supernatants were combined and layered over a discontinuous CsCl-gradient 
containing 3.5 ml CsCl density 1.2 g/ml and 3.5 ml of CsCl density 1.4 g/ml in a 
polypropylene tube (Beckman) for SW28i rotor. Particles were sedimented by 
ultracentrifugation for 4 h at 28,000 rpm (10°C). The visible virus band was 
harvested by a fine syringe (0.8 mm, Braun) puncturing the centrifugation tube 
carefully. To increase purity the obtained virus solution was adjusted 7 ml with 
dialysis buffer and centrifuged again in a CsCl gradient. Harvested virus was 
dialysed to remove excessive CsCl and stored at -80°C. Viral titers were 
determined for total and infectious particles. As this purification methods yield 
high amounts of purified virus it is required for execution of animal experiments. 
 
 
Adenovirus purification by Vivapure AdenoPACK 20  
 
According to the manufacturer’s protocol two flasks of infected HEK 293 cells 
were detached from the flask’s bottom and separated from the medium by 
centrifugation. Adenoviral particles were released from cells by freeze-thawing 
and centrifuged together with the retained supernatant (1,800 g, 5 min, 4°C). Free 
DNA was degraded by provided benzonase digestion (1h, 37°C) and major 
particles removed by filtration (0.45 µm). The resulting volume was mixed with 
1/9 volume of 10x loading buffer while constantly shaking to minimize osmotic 
shock. The solution (~ 20 ml) was applied to an equilibrated AdenoPACK 20 
Maxi Column and centrifuged (500 g, 5 min, 4°C) for membrane adsorption 
(Delmdahl, Nature Methods 3, (2006)). After washing twice with 1x washing 
buffer (18 ml) bound viral particles were eluted by 750 µl of the provided elution 
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buffer. The run-through solution was loaded again and incubated at RT for 10 min 
before centrifugation. Eluted particles were subsequently concentrated using the 
Vivaspin 20 centrifugal concentrator. Volume decreased from about 1,500 µl to 
300 – 500 µl and was determined approximately by pipette. For long time storage 
at -20°C the virus solution was mixed with the same volume of 2x storage buffer 
and stored under S2 conditions. Viral titers were determined for total and 
infectious particles. 
 
5.5.1.3 Determination of Adenovirus titer 
 
The infectious titer of the produced Adenoviruses was determined using the 
antibody-based Adeno-X Rapid Titer Kit (Clontech). According to the 
manufacturer’s protocol HEK 293 cells were used and infected with diluted virus 
solutions. After 48 h infected cells exposing Adenoviral hexon protein were 
immuno-stained by a specific antibody against hexon protein and a secondary 
antibody coupled to HRP. Stained cells were monitored in a bright field 
microscope, the number of primary infected cells per field of vision counted and 
the concentration of infectious viral particles (pfu/ml) calculated by the following 
formula: 
 
TiterInf  = (stained cells x field factor) / (V in ml x dilution factor) 
 
Field factor is provided by Clontech and depends on the object lens applied (79 for 
10x, 331 for 20x). 
In addition, the total number of viral particles (infectious and non-infectious) was 
determined by photometric measurement. 25 µl virus stock solution were solved in 
475 µl 0.1 % SDS and incubated at RT for 15 min to free DNA from particles. 
Optical density (OD) was determined and the total amount of Adenovirus particles 
calculated: 
 
Titerparticles = OD x dilution x 1012 
 
The ratio of total particles / infectious particles was used as a quality feature of the 
preparation. Usually at about 50 – 80 the ratio means only 1-2 % of purified viral 
particles form plaques in target cell layers. 
 
5.5.1.4 Determination of oncolytic potency (oncolysis assay) 
 
Target cells were seeded in 24 well plates (8x 104 cells or 1.6x 105 when 
doxorubicin was added) and grown over night. Certain virus solutions (100 µl) 
were applied to the cells for infection (8 h after chemotherapeutic treatment) at 
multiplicity of infections ranging from 5 to 0.0005. Cells were incubated until 
cytopathic effect was clearly visible by microscopic analysis (depending on the 
cell line 7 – 11 days). Viable cells were stained by crystal violet staining. 
Cells were washed with 1x PBS and fixed in 10 % formalin in 1x PBS for 10 min 
at RT. After washing with water cells were exposed to 0.1 % crystal violet (in 10 
% ethanol) and incubated for 30 min on a shaker. After washing and drying wells 
could be analyzed for cell lysis. Stained wells represent viable cells (without 
oncolysis). 
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5.5.2 Vesicular Stomatitis Virus (VSV) 
 
5.5.2.1 Preparation and storage 
 
Infectious viral particles of VSV were applied to confluent layers of the BHK-21 
derivative cell line BSR T7/5. Cells were incubated for 24 h, then, supernatant was 
collected and purified from cells and cell debris by centrifugation. Aliquots were 
prepared (~300 µl) and stored at -80°C. 
 
5.5.2.2 Determination of VSV titer 
 
The determination of VSV titers was usually conducted by TCID50 assay. To 
verify the obtained data plaque assay was run a few times. 
 
5.5.2.3 TCID50 
 
BSR-T7/5 cells were seeded in 96 well plates at a density of 1x 104 cells per well 
(100 µl) and grown over night. Single dilutions (10-5 – 10-12; 90 µl) of prepared 
infectious supernatants were applied to one row (12 wells) and incubated for 2 – 4 
days. Wells displaying a cytopathic effect were counted and processed according 
to Kärber’s statistical method. The results represent three independent 
measurements and are expressed as plaque forming untis per ml (pfu/ml). 
 
5.5.2.4 Plaque assay 
 
To determine VSV titer by plaque assay BSR T7 cells were seeded at 1.2x 106 
cells per 60 mm plate and incubated over night. After infection with dilutions of 
infectious supernatant cells were incubated 2 h at 37°C and then washed twice 
with 1x PBS to remove residual VSV particles. 3 ml of 1 % low melting agarose in 
growth medium were added to the plate and incubated at 4°C for 1 h to solidify the 
agarose layer. After returning to a 37°C incubator this layer maintains its gel-like 
constitution and prevents viral spreading over larger distances. Within 2-4 days 
visible plaques indicate cytopathic effect by VSV. These plaques were counted. 
The amount of plaques was multiplied with the dilution step and divided by the 
initial VSV containing volume of medium (in ml) to calculate the viral titer in 
pfu/ml. 
 
5.5.3 Retrovirus 
 
5.5.3.1 Cloning 
 
In this work constructed retroviral vectors were exclusively based on Clontech’s 
pQCXI plasmids with resistance genes for neomycin (pQCXIN) or puromycin 
(pQCXIP). Resulting viral particles are non-replicative and allow a rapid 
generation of stably expressing cell lines. 
 
The mentioned plasmids control expression of a desired gene by the CMV 
immediate early promoter. Genes were inserted by EcoRI and BamHI enzymes 
into the MCS succeeding the promoter. The expression of the selection marker was 
coupled by IRES to the expression of the genes of interest. Final DNA constructs 
were prepared as LPS free plasmids for transfection. 
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5.5.3.2 Production and application 
 
For production of non-replicative retroviral particles a 293 based amphotropic 
packaging cell line (phoenix cells) was utilized that provides certain retroviral 
genes (gag-pol, env) in trans. Resulting particles are infectious and integrate in the 
host cell’s genome but lack replicative capacity. 
 
Phoenix cells were seeded in two 60 mm plates (9x 105) and grown over night. 
The retroviral plasmid containing the gene of interest together with a plasmid 
coding for the glycoprotein of VSV were co-transfected using PEI. VSV-G allows 
transduction of a broad range of target cells. 1 h before transfection chloroquine 
(final concentration: 25 µM) was applied to the cells to increase transfection 
efficiency. After transfection fresh medium was added that was supplemented with 
2 % FCS only. 24 h later medium of the first plate was filtered (0.45 µm) and 
added to the target cells (about 25 % confluence) together with polybrene (final 
concentration: 8 µg/ml). After 4 h the process was repeated with the second plate 
of packaging cells. When viral transduction rate was insufficient larger volumes of 
virus solution were prepared and concentrated by ultracentrifugation. After the last 
transduction step medium was replaced by growth medium supplemented with the 
selecting chemical (neomycin or puroycin). 
After 14 days of selection cells were used for experiments. Expression of the 
inserted gene was controlled by western blot analysis. 
 
5.5.4 Lentivirus 
 
In contrast to retroviral vectors lentiviruses are usually used to transduce non-
replicating cells. In this work a lentiviral vector based on pLVTHM (Trono Didier, 
EPFL, Lausanne, Switzerland) – called NW4739 – was used to stably express 
shRNAs in human cells. NW4739 lacks H1 promoter and Tet operon between 
BamH I and Cla I.  
 
5.5.4.1 Cloning 
 
The GFP gene of NW4739 was replaced by the neomycin resistance gene from 
pQCXIN (pS5757) to allow for permanent selection of transgenic cells. In this 
vector the U6-promoter-shRNA-cassettes were inserted by BamHI and Xba I 
restriction enzymes. The resulting vectors were prepared as LPS free plasmids for 
transfection. 
 
5.5.4.2 Production and application 
 
To produce infectious lentiviral particles 293T cells were co-transfected with the 
lentiviral construct and three helper plasmids (pMDL g/p RRE, pMD-G, pRSV-
Rev) in a 10 cm dish. 24 and 48 h after transfection supernatants were collected, 
combined, filtered (0.45 µm) and centrifuged (SW32, 15,000 rpm, 90 min, 4°C) to 
increase concentration of viral particles. Huh-7 cells (60 mm plate, ~20 % 
confluence) were infected with the remaining lentiviral supernatant over night. 
Then, fresh medium containing neomycin was added to the target cells.  
Two weeks after the start of selection cells were used for experiments. The effect 
of the inserted shRNAs was checked by western blot analysis. 
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5.6 Animal experiments 
 
5.6.1 Application number 
 
Experiments regarding VSV were performed according to the German legal 
requirements (TierSchG). Number of application: 08/1569. 
 
5.6.2 Tumor inoculation 
 
6 – 8 weeks old nude mice from the Animal Research Institute of the MHH were 
anesthetized by diethyl ether and each mouse received 1x107 A549 cells in a total 
volume of 150 µl (adjusted with growth medium) subcutaneously in the right flank 
applying a syringe. Tumors were grown to an approximate size of 250 mm3 before 
experiment was started. 
 
5.6.3 Application of virus and chemotherapy 
 
Xeno-grafted mice were treated with 100 µl Doxorubicin (20 µg), 1x 107 
infectious particles wt-VSV (in 150 µl) or both treatments twice a week over an 
indicated period. Application of Doxorubicin occurred intravenously. 6 h later 
mice were infected intratumorally under diethyl ether anesthesia.  
 
5.6.4 Determination of tumor size 
 
Tumor size was measured every 5 days using a digital caliper and tumor volume 
was calculated by using the equation V (tumor) = (length x width2) / 2. 
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6. Results 
 
6.1 Development of conditionally replicating Adenoviruses harboring 
a self-destruction switch 
 
6.1.1 In vitro analysis of I-Sce I-cleavage capacity 
 
The major aim of this project was to design and construct conditionally replicating 
Adenoviruses that are degraded in p53-positive cells by the yeast endonuclease I-
Sce I. First, to basically understand I-Sce I-mediated cleavage and its properties to 
be applied in an adenoviral setting the enzyme and its activity were analyzed on 
plasmid basis under cell culture conditions. I-Sce I was derived from an expression 
vector containing a full length CMV promoter kindly provided by Toni Cathomen 
(Berlin). Since planned adenoviral target constructs for I-Sce I-mediated cleavage 
are DNA molecules situated in the cell nucleus, the enzyme should be efficiently 
translocated to this compartment since it is provide with an N-terminally nuclear 
localization sequences (NLS). Intracellular localization was determined by 
separation of nuclear and cytoplasmic compartments and subsequent western blot 
analysis. As shown in figure 5A, the majority of the endonuclease could be 
detected in nuclear extracts. Importantly, expression of I-Sce I did not impair cell 
morphology or growth indicating a non-genotoxic character of I-Sce I expression 
for human cells what is in concordance with literature data [82].  
In preliminary experiments, reporter plasmids were designed encoding only a 
single I-Sce I recognition sequence. Unfortunately, co-transfection of reporter and 
I-Sce I-encoding plasmids failed to result in a detectable cleavage activity. I-Sce I-
induced linearization was probably reversed by rapid and potent cellular DNA 
repair activities [152]. In order to unravel I-Sce I-cleavage activity, the 
experimental setup had to be changed to prevent the rapidly occurring repair of I-
Sce I-mediated DNA cleavage. Thus, the I-Sce I-target plasmids were modified, 
then encoding two I-Sce I-recognition sequences. 
Therefore, three constructs were designed to detect I-Sce I cleavage activity (figure 
5B). In a control vector, a CMV promoter was separated from a luciferase gene by 
a single I-Sce I recognition sequence. In two other plasmids, the CMV promoter 
controlled the expression of an EGFP gene that was enframed by two I-Sce I-
cleavage sites in directed (termed Sce_dir) or inverted (termed Sce_inv) direction. 
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Downstream of these sequences an intact luciferase gene was located. As cellular 
DNA repair mechanisms obviously efficiently reverse I-Sce I-mediated DNA-
double strand breaks, it was hypothesized that cleavage and repair of a reporter 
vector in a single-molecule-reaction resulted in increased luciferase activity. 
 
 
 
Figure 5. In vitro-analysis revealed nuclear localization and cleavage activity of I-
Sce I. (A) Cells were transfected with an plasmid encoding I-Sce I (+) or mock transfected 
(-). Nuclear and cytoplasmic compartments were separated and analyzed for I-Sce I 
presence by western blot analysis. (B) Schemes of I-Sce I-sensitive reporter vectors that 
were generated to act as targets for I-Sce I-cleavage. (C) HepG2 cells were co-
transfected with an I-Sce I expression vector and an indicated reporter vector in circular or 
linearied form. LacZ-normalized luciferase values were compared against the control (100 
%) and are depicted in relative values (mock-transfected cells resulted in relative 
luciferase activity of 0.2%) (data presented are means ± standard errors of the means 
(SEM). 
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For this purpose, HepG2 cells were co-transfected with an I-Sce I-encoding 
plasmid, one of the three I-Sce I-sensitive reporter vectors and an LacZ-encoding 
plasmid for normalization. With regard to the planned application (the adenoviral 
genome is linear), all reporter plasmids were tested in both circular and linearized 
form. Cells were harvested after 48 hours and luciferase activity was determined 
subsequently. In figure 5C, I-Sce I-expression is supposed to lead to excision of 
the EGFP gene in the reporter vectors containing two I-Sce I-cleavage sites. 
Religation of the promoter to the luciferase gene would allow expression of 
functional luciferase protein. In contrast, cleavage of the control vector results in 
rejoining of the promoter to the luciferase gene. Thus, measured activity from the 
control vector was set 100 %. Luciferase activities from the EGFP-containing 
vectors Sce_inv and Sce_dir were compared to the control plasmid. Circular 
Sce_inv and Sce_dir plasmids generated a markedly increased luciferase activity 
of 20 – 30 % of the control. Importantly, cells transfected with pBluescript instead 
of I-Sce I-encoding plasmid (mock-transfection) did only exhibit relative activities 
of 0.2 %. Thus, ligation of the luficerase gene to the CMV promoter implies I-Sce 
I-mediated excision of the EGFP gene. Backbone-cleavage of plasmids resulted in 
linearization to resemble the conditions in the adenoviral genome. As compared to 
the control vector, up to 85 % luciferase activity were measured.  
Results indicate that the expressed enzyme was functional since it specifically 
cleaved its recognition sequences. Interestingly, arrangement of the two I-Sce I-
sites relative to each other seems to be important for this setting as Sce_inv yielded 
significantly higher luciferase activity values than the plasmid containing the 
directed setup. 
 
6.1.2 Concept of I-Sce I-mediated destruction of the adenoviral vector in a p53-selective 
manner 
 
From results shown in figure 5, a concept was derived that is presented in figure 6. 
In an E1/E3-deleted adenoviral backbone an I-Sce I-recognition sites-enframed E1 
cassette was inserted. Downstream of the E1 region, a p53-dependent promoter 
(prMin-RGC) was inserted controlling the expression of the I-Sce I gene (figure 
6A).  
In this concept the adenoviral vector shall be inactivated by I-Sce I-mediated 
cleavage in the presence of transcriptionally active p53. As p53 allows expression 
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of I-Sce I, the enzyme recognizes its target sequences within the viral backbone. 
Ideally, complete cleavage should lead to separation of the E1A-controlling 
promoter from the E1A gene thus blocking E1A functions, and of the E1 cassette 
from the residual backbone (figure 6C). In contrast, in cancer cells with deleted or 
impaired p53 – resulting in loss of p53 transcriptional activity – I-Sce I is not 
expressed, the viral backbone remains intact and E1A is transcribed normally to 
allow for unaltered replication. Thus, due to the expression of E1A the infected 
cell initiates viral replication finally leading to release of adenoviral particles by 
cell lysis (figure 6C). 
 
 
Figure 6. Concept of a conditionally replicating adenoviral vector that harbors a 
p53-dependent self-destruction switch. (A) Linear adenoviral DNA of an E1/E3-deleted 
adenoviral vector harboring a modified E1 region. (B) In normal cells, p53 is 
transcriptionally active, thus binding to the p53-dependent promoter prMin-RGC (1) and 
allowing transcription (2) of the adenovirally encoded DNA-cleaving enzyme I-Sce. I-Sce I 
cleaves the DNA binding sequence (SCE) framing the adenoviral E1 genes within the viral 
backbone (3). I-Sce I-mediated cleavage disintegrates the viral backbone and 
consequently averts viral replication and cell lysis (4). (C) In tumor cells, p53 is often 
functionally inactivated or deleted. The p53-dependent promoter is silent and I-Sce I will 
not be expressed (1, 2). The viral backbone cannot be cleaved and remains functional (3). 
E1A is expressed and viral replication proceeds to final cell lysis (4). 
 
 
6.1.3 Generation of conditionally replicating adenoviral vectors 
 
The concept described above was realized employing the ligation method 
introduced by Mizuguchi and Kay [153]. The backbone vector pAdHM4 contains 
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an E1/E3 deleted adenoviral genome flanked by Pac I recognition sites to produce 
a linear adenoviral DNA [153]. In this vector, recombinant E1 regions were 
inserted (figure 7A, B). In all viruses, the native E1A gene was replaced by an N-
terminally truncated mutant (deletion of 66 bp) lacking amino acids 3 – 25 to 
inhibit binding to CBP/p300 and p53. E1A transcription was controlled either by a 
small CMV (230 bp) promoter or an hTERT promoter. Human cancer cells 
frequently activate the hTERT promoter. Since this is in stark contrast to normal, 
differentiated human cells it can be exploited to increase selectivity of oncolytic 
viruses (reviewed in [154]). Further, these promoter fragments were attached to 
binding sites of Gal4. Resulting promoters have been reported to be sensitive to 
the expression of the fusion protein Gal4-KRAB leading to inactivation of the 
expression unit. While the Gal4-domain mediates specific DNA-binding, Krüppel-
associated box (KRAB) domains are potent transcriptional repression modules 
[74]. This construction allows for combination of the destruction switch concept 
with the p53-dependent transcriptional repressor termed Gal4-KRAB via an 
internal ribosomal entry sequence (figure 7B). The complete E1 region (E1A and 
E1B genes) was flanked by two inverted I-Sce I recognition sequences. Thus, 
complete I-Sce I-cleavage would excise the region of the adenoviral genome that is 
essential for initiating viral replication. 
 
 
 
Figure 7. Basic setup of the E1 regions of conditionally replicating Adenoviruses 
harboring a self-destruction switch or EGFP. E1 genes are flanked by inverted I-Sce I-
recognition sites (Sce) and are controlled by a CMV230-promoter. Alternatively, instead of 
the CMV fragment a hTERT promoter was used (not shown; entitled analogously). Instead 
of the native E1A gene a N-terminally deleted mutant (del 66 bp) is used for all viruses. 
(A) The p53-dependent prMin-RGC promoter controls the expression of I-Sce I or EGFP. 
(B) In an additional setup, the I-Sce I-concept is combined with the application of the 
transcriptional repressor Gal4-KRAB that silences the promoter controlling the E1A gene. 
This artificial promoter contains 15 target sequences (G4K) for the Gal4-DNA binding 
domain of the fusion protein. Transcriptional repression is mediated by the KRAB domain. 
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Stepwise construction of the heterologous E1 region was examined by restriction 
enzyme cleavage and functional assays (data not shown) to ensure integrity of the 
final constructs. After production of infectious viral particles from the resulting 
plasmids the expression patterns of the resulting viruses were analyzed by western 
blotting (figure 8). Both I-Sce I and EGFP (in the control vectors) were expressed 
properly. Gal4-KRAB was correctly expressed by the viruses encoding the 
transcriptional repressor. 
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Figure 8. Expression patterns of the recombinant adenoviral vectors. p53-positive 
A549 cells were transduced with recombinant Adenoviruses as indicated at MOI = 5. 
Protein expression was controlled 40 hours post infection by western blot analysis. (In 
viruses, Gal4-KRAB is abbreviated by G4K.) 
 
 
In summary, eight conditionally replicating Adenoviruses were generated that 
express certain regulatory proteins including the yeast meganuclease I-Sce I and 
the fusion protein Gal4-KRAB in a p53-selective manner.  
 
6.1.4 Adenovirus-encoded I-Sce I recognizes and cleaves its target sequences within the 
viral backbone 
 
As shown above in figure 5, the capacity of I-Sce I to recognize and cleave its 18 
bp long recognition sequence was analyzed in cell culture on plasmid level. To 
determine the activity that was originated from virus-encoded I-Sce I, it was 
assumed again that mammalian cells rapidly react on generation of DNA double 
strand breaks in the above described manner. Figure 9A shows examples of 
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reorganized adenoviral DNA after I-Sce I-cleavage and repair. It was hypothesized 
that the E1 region following excision could preferably be circularized in an intra-
molecular reaction by DNA repair mechanisms. This molecule is theoretically 
detectable by a specific PCR where primers will be elongated across the religation 
point (figure 9A) thus rendering the reaction unique for this circular DNA 
molecule.  
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Figure 9. Adenovirus-encoded I-Sce I is expressed in p53-positive cells and cleaves 
its recognition sequence. (A) Cleavage of recombinant adenoviral DNA molecules 
activates cellular DNA repair mechanisms finally leading to a variety of possible cleavage-
religation products. The majority of these products should remain linear except of excised 
E1 regions. These about 3,000 bp large fragments can be religated to circular DNA 
molecules in an intra-molecular-reaction (size not to scale). Design of a PCR that 
amplifies sequences across the religation point (about 650 bp product size) allows for 
detection of these molecules. (B) Agarose-gel analysis of a PCR that was performed on 
purified DNA from cells infected with an I-Sce I-encoding virus for 24 hours. Subsequent 
DNA sequencing confirmed the nature of the resulting DNA fragment. 
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Figure 9B represents the results of the experiment to determine I-Sce I-activity. 
p53-positive A549 cells and Huh-7 cells that harbor a transcriptionally inactive 
p53 mutant were infected with a low MOI of Ad-CMV-Sce or the control virus 
Ad-CMV-EGFP. DNA was extracted 24 hours after infection and subjected to 
PCR analysis. Whereas neither adenovirally infected Huh-7 cells nor Ad-CMV-
EGFP infected A549 cells produced any detectable PCR product, a DNA fragment 
of about 650 bp could be amplified from A549 cells infected with the I-Sce I-
encoding virus (figure 9B). Product size matched calculated length and thus, 
further was analyzed by DNA sequencing revealing the 650 bp fragment to contain 
E1A and E1B sequences fused to an I-Sce I-site. 
Taken together, it was demonstrated that I-Sce I-harboring adenoviral vectors can 
be cleaved specifically by the encoded endonuclease. Thus, certain cleavage 
products have been detectable for Sce-viruses but not for EGFP-encoding control 
viruses. Furthermore, application of the prMin-RGC-promoters resulted in a 
limitation of endonucleolytic activity to p53-positive cells. These results provide 
evidence that I-Sce I can be successfully applied in the designed concept. 
 
6.1.5 I-Sce I-encoding Adenoviruses are superior to their EGFP controls in terms of 
selectivity regarding p53-selectivity 
 
In this work, recombinant adenoviral vectors were designed that replicate p53-
selectively based on a novel regulation mechanism. Data obtained in preceding 
experiments (figure 8) revealed that constructed viruses did show the correct 
expression patterns of regulatory proteins. Furthermore, expression of the virus-
encoded endonucleolytic enzyme I-Sce I was capable to cleave certain inserted 
target sequences within the adenoviral backbone in p53-positive cells (figure 9). In 
a subsequent experiment is was analyzed whether these data finally lead to a 
restriction of amplification of the recombinant vectors in p53-positive cell lines 
(A549, HepG2) compared to p53-dys-functional cells (Huh-7, H1299, Hep3B). 
Oncolytic activity was assessed 7 to 10 days after infection by crystal violet 
staining. In cells that possess only inactivated or even no p53 all viruses exhibited 
a lytic behavior (Figure 10, left panel). Importantly, corresponding I-Sce I and 
EGFP-control viruses did not show differences in their lytic capacities. 
Nonetheless, viruses using a CMV promoter to control the E1A gene exhibited a 
slightly higher lytic power than the hTERT-viruses. Since I-Sce I was expressed in 
6. RESULTS  59 
   
a p53-dependent manner, a regulation could only be expected in the p53-positive 
cell lines depicted in figure 10, right panel. In A549 cells, Ad-CMV-Sce lysed 
cells only at much higher employed MOIs than its control vector Ad-CMV-EGFP. 
The results correspond to hTERT-vectors where I-Sce I-expression led to reduced 
oncolysis. In HepG2 cells, the combination of I-Sce I with the transcriptional 
control of E1A by the hTERT promoter resulted in higher selectivity. Surprisingly, 
this was not observed in A549 cells. 
 
 
 
Figure 10. Oncolytic activity of recombinant adenoviral vectors in cells with 
transcriptionally active and impaired p53. Human cancer cell lines were seeded in 24 
well plates and infected with decreasing amounts (resulting in MOIs 20 – 0.0005) of the 
indicated viruses. 8 hours prior to infection cells were supplemented with 50 ng/ml 
Doxorubicin to activate p53 protein. Repeated infection cycles were allowed for 7 – 11 
days depending on the cell line. Cell staining was performed with crystal violet. Blue areas 
indicate non-lysed cells whereas unstained wells indicate extensive viral cytolysis. (Huh-7, 
mut-p53; H1299 and Hep3B, p53-deleted; A549 and HepG2, wt-p53) 
 
 
Vectors applying the additional regulatory mechanism of Gal4-KRAB did exhibit 
an I-Sce I-regulation as well (in A549, HepG2). However, compared to I-Sce I-
only viruses the extent was lower (half to one log step). Noteworthy, combining 
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the Gal4-KRAB and the I-Sce I regulation mechanisms resulted in a gain of 
selectivity. 
Induction of a cytopathic effect in Huh-7, H1299 and Hep3B cells differs 
markedly. Beside replication, the infectivity of a particular cell type contributes to 
the oncolytic effect of a given vector [155]. Considering the results of the control 
viruses (wt-Ad5, ONYX-015, Ad-CMV-Gal4-KRAB) indicates that Huh-7 cells 
can not be infected as good as H1299 or Hep3B cells by adenoviral vectors. 
Importantly, there were no or only very limited (hTERT-viruses in H1299) 
differences between an I-Sce I-encoding virus and its corresponding EGFP-control 
virus.  
In conclusion, recombinant adenoviral particles have been constructed that were 
demonstrated to be regulated by a p53-dependent endonucleolytic switch. 
Resulting, viral replication is highly restricted in wt-p53 cells, whereas oncolytic 
potency was not impaired in cell lines harboring dys-functional p53. This clearly 
indicates the functionality of the regulation concept employing I-Sce I. 
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6.2 Vesicular Stomatitis Virus 
 
In a second project the virus-host interaction of a natural tumor virus – Vesicular 
Stomatitis Virus (VSV) – were analyzed in human cancer cell lines. Special 
interest was paid to the action of the Bcl-2-family members that are involved in 
regulating apoptotic cell death. 
 
6.2.1 VSV-mediated decrease of Mcl-1 in human cancer cell lines 
 
In order to analyze levels of proteins of the Bcl-2-family following VSV-infection, 
human cancer cell lines were infected with wild type VSV (Indiana) at MOI 0.1 
and protein lysates were prepared (up to 48 hours post infection) with special 
interest on apoptosis-related proteins. Within the first 6 – 10 hours after infection a 
rapid decline of cellular levels of myeloid cell leukemia 1 (Mcl-1 ) protein was 
observed (figure 11A) in all tested cell lines. In contrast, levels of all other proteins 
including pro- and anti-apoptotic members of the Bcl-2 family as well as p53 
remained unchanged. Elimination of Mcl-1 seems to be independent of the p53 
status of an infected cell since p53 positive (HepG2, A549), mutant-p53 
expressing (Huh-7) and p53-negative (H1299, data not shown) cell lines were 
affected similarly in a comparable time frame. Unfortunately, it was not possible 
to detect transcriptional activation of the pro-apoptotic genes Puma (p53 target 
gene) and Noxa (by a p53 independent mechanism) that has been described 
elsewhere [94;116;156]. 
Mechanisms that lead to the destruction of Mcl-1 could be the following: first, it 
has been reported that Mcl-1 is specifically cleaved by caspase-3 at Asp-127 and 
Asp-157 inhibiting its pro-survival function [157-161]; further, Mcl-1 protein 
levels are reported to be regulated by ubiquitin-mediated proteasomal degradation 
through the ubiquitin E3 ligase MULE/LASU1 [162;163]; additionally, an enzyme 
related to growth factor pathways, glycogen synthase kinase 3 beta (GSK-3β), 
targets Mcl-1 for destruction by specific phosphorylation at Ser159 located within 
the PEST domain of Mcl-1 that subsequently leads to proteasomal degradation via 
a different E3 ligase called β-TrCP [164]. Additionally, it can not be excluded that 
VSV proteins directly degrades Mcl-1 or targets Mcl-1 for degradation. To test 
caspase and proteasome dependence of the VSV-mediated Mcl-1 decrease, A549 
cells were infected with VSV (MOI = 0.1) and concurrently treated with potent 
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pan-caspase (z-VAD-fmk) or proteasome inhibitors (MG132) for up to 12 hours 
(figure 11B). Z-VAD-fmk-treated cells showed kinetics of Mcl-1 decrease 
comparable to cells infected with VSV only. In contrast, proteasomal inhibition 
strongly stabilized the protein indicating that following VSV-infection Mcl-1 is 
not cleaved by activated caspases but is preferentially targeted for degradation via 
the ubiquitin-proteasome pathway by an unspecified E3 ubiquitin ligase.  
 
 
 
Figure 11. Decrease of Mcl-1 protein levels following VSV infection depends on 
VSV-mediated block of de novo proteins synthesis and proteasomal degradation of 
Mcl-1. (A) Human cancer cell lines were infected with wt-VSV (MOI = 0.1) and levels of 
apoptosis-related proteins were determined by western blotting. (B) A549 cells were 
infected with wt-VSV (MOI = 0.1) alone (control) or in combination with the pan-caspase-
inhibitor z-VAD-fmk (20 µM; z-VAD) or the proteasome inhibitor MG132 (20 µM). Cell 
lysates were analyzed by western blotting. (C) A549 cells were treated with various 
concentrations of the transcription inhibitor Actinomycin D (Act D) and harvested after 6 h. 
Alternatively, A549 cells were treated with 1 µg/ml Actinomycin D, harvested after 
indicated times (h) and then subjected to western blot analysis. (D) HepG2 cells were 
infected with mutant VSV (attenuated virus 1, AV1) at MOI = 0.1 and harvested after the 
indicated times. Protein extracts were prepared and analyzed by western blotting for Mcl-1 
and actin. 
6. RESULTS  63 
   
In general, Mcl-1 is rapidly turned over and, thus possesses a short half-life of 
smaller than 2 hours depending on the cell line [165-168]. VSV is known to block 
cellular protein biosynthesis globally by several mechanisms. This disrupted 
production of host cell proteins in conjunction with a constitutive protein 
degradation via the proteasome leads to rapidly declining levels of short-lived 
proteins – explaining Mcl-1’s elimination following VSV infection. In an attempt 
to investigate inhibition of cellular protein biosynthesis separated from other viral 
effects, A549 cells were treated with different concentrations of the transcription 
inhibitor Actinomycin D (Act D) and harvested after 6 hours or after up to 36 h 
(figure 11C). Resulting data clearly showed that effects of Act D-induced block of 
transcription on cellular Mcl-1 protein levels resemble those elicited by VSV. 
Comparable data have been achieved for Huh-7 cells (data not shown).  
The attenuated VSV mutant AV1 is unable to inhibit export of host mRNAs from 
the nucleus to the cytoplasm [94]. Following, the protein expression of AV1-
infected cells was demonstrated to act normally [94]. In order to analyze the effect 
of AV1 on the Mcl-1 level of human cancer cells, HepG2 cells were infected with 
AV1 (MOI = 0.1) and protein lysates were prepared every 12 hours (0 – 48 h). 
Western blot analysis clearly showed that AV1 – in contrast to wt-VSV – does not 
induce a decline of cellular Mcl-1 protein levels (figure 11D). Thus, it can be 
assumed that VSV-mediated block of cellular protein synthesis in conjunction with 
normal proteasomal degradation leads to the observed Mcl-1 decrease.  
Collectively, these data for the first time show that wt-VSV infection leads to a 
rapid decline of Mcl-1 protein level based on rapid proteasomal degradation. A 
similar decrease could not be observed for other pro- or anti-apoptotic Bcl-2-
family members in these experiments. 
 
6.2.2 VSV induces apoptosis via a strong activation of caspase-3 
 
It has been demonstrated previously, that wt-VSV infection leads to induction of 
apoptosis via caspase-9 and caspase-3-like proteases [124;169]. This indicates the 
involvement of the intrinsic pathway in wt-VSV-mediated apoptosis induction. 
To test whether VSV is capable to induce apoptosis in the used human cell lines 
caspase-3 activation was measured (figure 12). In HepG2 and Huh-7 cells caspase-
3 activities reached comparable top levels at 24 to 36 hours while those of 
uninfected controls remain low. In contrast, infected A549 cells exhibited only 
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about 10 % of these activities culminating at 36 hours. A typical cytopathic effect 
of VSV is rounding of the infected cell after induction of apoptosis [170]. This 
effect was detectable by bright field microscopy for all three cell lines. 
 
 
Figure 12. Human cancer cell lines induce apoptosis by activation of caspase-3 
following infection with wt-VSV. A549, HepG2 and Huh-7 cells were infected at low 
MOIs (MOI = 0.1) of wt-VSV (black marks) or left uninfected (open marks) and harvested 
after indicated times. Caspase-3 activity was calculated in fluorescence units per µg 
protein and hour. Data represent results of three independent measurements and are 
presented as means ± standard errors of the means (SEM). 
 
 
 
6.2.3 VSV mediates cleavage and subcellular relocalization of LC3 indicating induction 
of autophagy 
 
Accompanied with apoptosis, is was reported that VSV induces autophagy in 
plasmacytoid cells and mouse embryo fibroblasts [171;172]. Autophagy is not 
only another programmed cell death mechanism but is additionally known to be 
part of the innate and adaptive immune response against viral infections [171]. To 
analyze induction of autophagy in human cancers the fusion protein of LC3 and 
YFP was applied. LC3B is a mammalian autophagy associated protein 8 (Atg8) 
homologue that is widely used as marker for autophagy. Induction of autophagy is 
known to coincide with cleavage of LC3 into LC3-I and -II and subsequent 
relocalization to nascent autophagolysosomal structures [151].  
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Figure 13. VSV infection induces autophagy in human cancer cell lines. Transgenic 
cells expressing the fusion protein YFP-LC3 were treated with wt-VSV (MOI = 10), wild 
type human Adenovirus type 5 (MOI = 10) or the autophagy-inducing agent chloroquine 
(25 µM). (A) Time courses of autophagy induction by chloroquine, VSV and wt-Ad5. After 
treatment cells were analyzed by western blotting. Generation of cleaved LC3-YFP (lower 
band) indicates induction of autophagy. (B) Human cancer cell lines stably expressing 
YFP-LC3 were infected with wt-VSV (MOI = 0.1) and protein extracts were analyzed for 
YFP-LC3 cleavage by western blotting. (C) Transgenic human cancer cell lines A549 and 
Huh-7 were treated like indicated (control = untreated, CQ = 25 µM, VSV-MOI = 0.1) and 
analyzed by confocal laser scanning microscopy after 12 h. YFP-signals (green), nuclear 
staining with To-Pro3 (red) and merged pictures are shown. Formation of 
autophagolysosomal structures can be observed by emergence of YFP-LC3-foci in 
contrast to diffuse distribution in untreated cells (control). 
 
 
Following treatment with the potent autophagy inductor chloroquine (25 µM; CQ) 
LC3 was rapidly cleaved in stably transfected A549 cells (Figure 13A, left image). 
Infection with VSV or human wt-Adenovirus type 5 at MOIs = 10 revealed LC3-
cleavage and, thus induction of autophagy (figure 13A, right image). Weaker 
protein levels in case of VSV (for 24 – 48 hours) are an effect of the virus-
mediated block of protein production impairing the levels of the YFP-LC3. 
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Cleavage of LC3 could be detected in all three cell lines analyzed (figure 13B) 
even when low viral multiplicities (MOI = 0.1) were used. In addition to western 
blot analysis, induction of autophagy by VSV was confirmed by confocal laser 
scanning microscopy (CLSM)-aided monitoring of the relocalization of YFP-LC3 
to focused dots representing autophagolysosomes (figure 13C). In summary, the 
data indicate that VSV-induced apoptosis in human cancer cell lines is 
accompanied by induction of autophagy. 
 
6.2.4 Effects of Mcl-1 on activation of apoptosis and VSV amplification 
 
Previous results indicated that proteasomal degradation is responsible for Mcl-1 
elimination from VSV-infected cells (figure 11). To analyze more in detail the 
underlying mechanisms that target Mcl-1 for degradation an ubiquitination-
resistant mutant of Mcl-1 (mut-Mcl-1) was used (kindly provided by Xiaodong 
Wang, Dallas, TX, USA) where crucial lysine residues (targeted by 
MULE/LASU1) were replaced by alanines [162]. Cells harboring a Mcl-1 protein 
that can not be ligated to ubiquitin by MULE/LASU1, will not be normally 
processed by proteolytic activity of the proteasomes [162]. Then, A549 and Huh-7 
cells stably over-expressing wild type- or mutant-Mcl-1 were infected with wt-
VSV and Mcl-1 protein levels up to 36 hours post infection were compared (figure 
14A). While in parental cell lines Mcl-1 decreased rapidly, wt-Mcl-1-over-
expressing cells showed a markedly prolonged presence of the protein. Thus, mut-
Mcl-1 was detectable in VSV-infected cells up to 36 hours. The anti-apoptotic 
effect of Mcl-1 was analyzed by monitoring VSV-induced apoptosis in parental 
and transgenic (wt-Mcl-1, mut-Mcl-1, EGFP) A549 and Huh-7 cells. Results 
represented in figure 14B showed an impressive decrease of caspase-3 induction 
for both wt- and mut-Mcl-1-over-expressing cells in contrast to parental and 
EGFP-over-expressing controls. While A549 cells reached highest activation 
levels around 36 hours, Huh-7 values culminated earlier at about 24 hours post 
infection. To test whether increased Mcl-1 protein levels affect virus amplification, 
supernatants of infected cells were harvested every 12 hours to monitor produced 
viral progeny for a given period of time (figure 14C). Mcl-1 over-expression 
increased the produced VSV level at a statistically significant basis for all three 
time points. This might be directly attributed to lower levels of apoptosis induction 
for cells over-expressing mut-Mcl-1 (figure 14B). 
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Figure 14. Over-expression of wt-Mcl-1 or mut-Mcl-1 impairs induction of apoptosis 
in wt-VSV-infected human cancer cells. (A) Native A549 and Huh-7 cell lines and wt- or 
mut-Mcl-1-over-expressing derivatives were infected with wt-VSV (MOI = 10). Protein 
levels of Mcl-1 and actin were analyzed by western blotting to determine effect of VSV-
infection on cellular levels of the over-expressed Mcl-1 proteins depending on the time 
post infection. (B) Parental and transgenic A549 and Huh-7 cells expressing wt-Mcl-1, 
mut-Mcl-1 or EGFP were infected with wt-VSV (MOI = 0.1) and harvested after the 
indicated time points. Caspase-3 activity indicating induction of apoptosis was determined 
(data presented are means ± standard errors of the means (SEM)). (C) Parental and 
indicated transgenic A549 cells were infected with wt-VSV (MOI = 0.1). Supernatants 
were collected after the indicated times and viral titers were determined by TCID50 
analysis. Statistically significant differences were calculated from three experiments by 
Mann-Whitney-Test (*; p < 0.05). 
 
 
Taken together, over-expression of wt-Mcl-1 and a stabilized ubiquitination-
resistant mutant of Mcl-1 led to an increased protein level of Mcl-1 in VSV- 
infected human cancer cells. Increased protein levels subsequently impaired 
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induction of apoptosis measured by caspase-3 induction. Protein stabilization and 
less activation of the apoptotic cell death pathway coincided with higher viral 
titers. 
 
6.2.5 Mcl-1 does not influence VSV-induced autophagy 
 
 
 
Figure 15. Induction of autophagy by wt-VSV is not influenced by over-expression 
of wt- or mut-Mcl-1 in human cancer cells. (A) Transgenic A549 cells expressing YFP-
LC3 or YFP-LC3 and mut-Mcl-1 were infected with wt-VSV (MOI = 10). Western blot 
analysis determined LC3-cleavage and the Mcl-1 status. (B) The same transgenic cells 
were infected with VSV (MOI = 0.1), treated with chloroquine (CQ, 25 µM) or left untreated 
(control). Formation of autophagolysosomes indicating induction of autophagy was 
monitored by confocal laser scanning microscopy after 12 h (MOI = 0.1). Depicted are 
YFP-signals (green), nuclear staining with To-Pro3 (red) and merged pictures. 
 
 
Beside apoptosis, VSV was observed to induce autophagy in human cancer cell 
lines (figure 13). As Mcl-1 significantly influences VSV-induced apoptosis (figure 
14B), its actions on autophagic cell death were analyzed as well. For this purpose, 
A549 cells were stably transfected with YFP-LC3 alone or YFP-LC3 and the 
ubiquitination-resistant Mcl-1 mutant. Western blot analysis revealed no 
significant differences regarding the emergence of the LC3-cleavage product 
(figure 15A). To underpin this result, both cell lines were infected with low MOIs 
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of wt-VSV and 12 h post infection monitored for YFP-LC3-localization using 
CLSM. The typical formation of focused YFP-LC3 signals occurred in both cell 
lines independent of the Mcl-1 status (figure 15B). Whereas, untreated controls did 
not show any differences in both transgenic A549 cell lines, the number and 
intensity of the YFP-LC3-dots appeared to be minimally increased in CQ- and wt-
VSV-treated A549-YFP-LC3-mut-Mcl-1 cells compared to A549-YPF-LC3 cells. 
Thus, microscopic data support the notion that Mcl-1 does not or not detectably 
influence induction of autophagy by wt-VSV. 
 
6.2.6 Combination of VSV-virotherapy and Doxorubicin chemotherapy 
 
Over-expression of Mcl-1 is known to confer resistance to chemotherapeutic 
treatment in different human cancers [173;174]. Hence, virotherapy-mediated 
reduction of Mcl-1 protein levels would greatly improve treatment opportunities. 
As VSV infection rapidly leads to decreased levels of Mcl-1 (figure 11) it should 
be tested if the potential of combined treatment with VSV and Doxorubicin to 
induce apoptosis exceeded that of single treatments.  
A549 and Huh-7 cell lines over-expressing EGFP or mut-Mcl-1 were treated either 
with 100 ng/ml Doxorubicin or VSV (MOI = 0.1) or with a combination of 
Doxorubicin and VSV. Activation of caspase-3 was determined 24 h post infection 
(figure 16A). In general, expression of mut-Mcl-1 reduced apoptosis induction as 
already shown in figure 14B. A549 and Huh-7 cells expressing mut-Mcl-1, 
application of Doxorubicin did not or only slightly amplify the caspase-3-signal. In 
contrast, in control cells expressing EGFP instead of Mcl-1 caspase-3 values of 
combined treatment outstripped those of VSV single treatment of about 25 % in 
A549 and 50 % in Huh-7. This difference was statistically significant. 
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Figure 16. Combination of VSV-virotherapy and chemotherapy. (A) Transgenic A549 
and Huh-7 cells expressing EGFP or mut-Mcl-1 were exposed to 100 ng/ml Doxorubicin 
(Dox), VSV (MOI = 0.1), a combination of both or left untreated and activation of caspase-
3 was determined after 24 h. (B) Knock-down transgenic derivatives of Huh-7 cells 
expressing shRNAs against Bax, Bak or both were generated and effect on the indicated 
protein levels was determined by western blot analysis. (C) Knock-down transgenic 
derivatives of Huh-7 cells were subjected to caspase-3 activation analysis under indicated 
treatment strategies (100 ng/ml Doxorubicin, VSV-MOI = 0.1). Significance of differences 
was calculated using Mann-Whitney-Test (*; p < 0.05). (D) A549 and Huh-7 cells were 
treated with 100 ng/ml Doxorubicin (Dox) or 10 µg/ml 5-Fluorouracil (5-FU) in combination 
with VSV or exclusively with VSV (MOI = 0.1). Supernatants were collected every 12 
hours and viral titer was determined by TCID50 analysis (result of three measurements is 
shown). In general, data presented are means ± standard errors of the means (SEM). 
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Mcl-1, in concert with its pro-apoptotic binding partners Bak and Bax, regulates 
the permeability of the mitochondrial outer membrane. Therefore, the involvement 
of Bax and Bak in VSV-mediated apoptosis and chemotherapy-induced caspase-3 
activation was analyzed in Huh-7 cells stably expressing shRNAs directed against 
Bax, Bak or both proteins (figure 16B). Silencing of Bax and Bak resulted in a 
strong reduction of caspase-3 activation in VSV or combination-treated cells 
(figure 16C). In contrast to control cells (parental, scrambled shRNA), knock-
down of Bax and/or Bak led to an impaired sensitization of virally transduced 
tumor cells against chemotherapy.  
An important prerequisite for the application of oncolytic viruses in combination 
with conventional chemotherapy is an unimpaired viral replication to maintain 
virotherapeutic efficacy. The influence of chemotherapy on viral amplification was 
assessed for Doxorubicin (100 ng/ml) and 5-Fluorouracil (10 µg/ml) by 
determining viral offspring in the supernatants of infected cells produced in 12 
hours-periods in the course up to 48 hours post infection. Results of figure 16D 
demonstrated that VSV replication is not altered by therapeutically relevant 
concentrations of the applied chemotherapeutic agents.  
In summary, VSV-mediated decrease of cellular Mcl-1 protein level could be 
rescued either by stabilization of Mcl-1 or by knock-down of the pro-apoptotic 
Mcl-1 binding partners Bax and Bak. It could be demonstrated that 
chemotherapeutic treatment does not interfere with viral replication. 
 
6.2.7 Combination of VSV and chemotherapy enhances treatment efficacy of xeno-
transplanted human tumors in vivo 
 
Data obtained in vitro as described above suggest a relation between VSV and 
Mcl-1 that can be therapeutically exploited by additional chemotherapy to enhance 
apoptosis. Confirmation of this principle in vivo would greatly support the 
significance of in vitro results. For this purpose, A549 tumors were inoculated in 
nude mice and grown tumors were treated with a combination of 20 µg 
Doxorubicin intravenously and 1x 107 particles VSV intratumorally twice a week. 
Figure 17A illustrates the treatment success by development of the tumor size. 
Untreated or Doxorubicin-treated tumors constantly grew without a detectable 
difference. In contrast, tumors treated with VSV showed a marked delay of 
growth. Only application of the combined virochemotherapy was capable to 
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induce shrinkage of tumor size (of about 10 %) demonstrating the therapeutic 
succes. These results were supported by HE stained tumor sections (figure 17B) 
that were prepared from the treated tumors after day 40. VSV alone caused areas 
of cytopathic effects (no cell nuclei detectable, loss of normal cell morphology) 
that were significantly enlarged when tumors were treated with VSV and 
Doxorubicin in combination. 
  
Figure 17. Destruction of xeno-transplanted A549-tumors on nude mice is superior 
for combination over single treatments. A549 tumors were implanted on nude mice 
and treated twice weekly with 20 µg Doxorubicin intravenously and/or 1x 107 infectious 
VSV particles intratumorally or left untreated (four groups each of 6 animals). Tumor 
growth was assessed every 5 days by a digital caliper. (A) Tumor volume was calculated 
and is depicted in relative representation (day 0 = 100 %), statistical significance was 
determinded by Mann-Whitney-Test (*; p < 0.05). Data presented are means ± standard 
errors of the means (SEM). (B) Mice were sacrificed at day 40 and tumors were 
embedded in paraffin and sections stained with hematoxylin/eosin. Areas displaying 
cytopathic effects are encircled. 
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Further experiments were performed to analyze this effect more in detail. 
Detectable effects of VSV treatment on the molecular level in vivo such as 
apoptosis induction or viral spreading are only hard to investigate when tumors 
were infected for several times over a long period of time like described for figure 
17. Consequently, the experimental setting was altered. A549 tumors on nude mice 
were treated with Doxorubicin and VSV alone or in combination. In contrast to the 
formerly depicted experiment (figure 17), treatment was performed only once and 
tumors were harvested 1, 3 or 5 days later. Immuno-histochemical staining (anti-
VSV-G-staining) of tumor sections was performed. In uninfected tumors, VSV-G 
was not detectable (figure 18A). In tumors that had been treated with VSV with or 
without additional Doxorubicin application the resulting staining reveals the 
presence of VSV-G protein. However, VSV-G appeared to be rather weak and can 
not be satisfyingly detected. HE staining from figure 17B demonstrated extensive 
cytopathic effects for VSV-infected tumors, so presence of VSV is necessary for 
this effect. Staining would be expected to be near to or at the rim of the destroyed 
tissue area. It might be speculated whether VSV in general spreads very slowly or 
cytopathic effect occurs only after repeated virus application. Other reports 
depicting vast intra-tumoral spreading of VSV were performed in rats and applied 
monoclonal mouse-anti-VSV-G antibodies [136;175-177]. This antibody would 
not be applicable in the used mouse model. Surprisingly, literature provides only 
very few references demonstrating histological staining of intra-tumoral VSV-
spreading in mice by applying polyclonal antibodies against VSV-G. However, 
presented images have not achieved quality of results obtained within rats [149]. 
Thus, presumably intratumoral VSV-G detection is limited by technical reasons 
indicating the need for a potent, non-murine antibody for IHC applications. 
Consequently, in vivo-data could not prove differences between treatment 
strategies regarding viral spreading (figure 18A). On the other hand, this would be 
in concordance with results obtained from cell culture experiments where viral 
replication was not affected by chemotherapy (figure 16D). 
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Figure 18. Biochemical analysis of tumor sections. A549 tumors were implanted on 
nude mice, treated once as indicated (1x107 VSV particles intratumorally, 20 µg 
Doxorubicin (Dox) intravenously), harvested after 1, 3 or 5 days and embedded in paraffin. 
(A) Paraffin sections (day 5) were stained for VSV surface glycoprotein compared to an 
isotype control. Brown dots (marked with arrows) indicate areas of VSV presence. (figure 
is continued on next page) 
 
 
Induction of apoptosis in vivo was assessed by detecting apoptotic cells by 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
(figure 18B). Untreated tumors (control) did not show any TUNEL-positive 
signals. Doxorubicin-treated tumors exhibited only a small fraction of cells that 
underwent apoptosis (figure 18B, left column), however, TUNEL-signals increase 
up to day 5. VSV is a potent inducer of apoptosis in xeno-transplanted tumors 
since figure 18B demonstrated an impressive TUNEL-signal already 24 hours after 
VSV infection (middle column). Yet, in concordance with in vitro results, 
combination of chemotherapy and virotherapy was demonstrated to induce 
apoptosis at an even higher fraction of cells (figure 18, right column, days 3 and 
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5). As TUNEL signals multiply for days 3 and 5 compared to day 1 viral spreading 
must have occurred. Together, both results of apoptosis induction (TUNEL assay) 
and the observation of an amply cytopathic effect by HE staining contrast the 
results from immuno-histochemical analysis of infected tumors. 
 
 
 
Figure 18. Biochemical analysis of tumor sections (continued). (B) Detection of 
apoptotic cells was performed by staining DNA nicks by TUNEL assay (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) (green signals), cell nuclei were 
colored by DAPI-staining (blue). Representative pictures were chosen for display.  
 
 
Concluding, results from the here illustrated in vivo experiments demonstrate that 
VSV-mediated down-regulation in vivo can be exploited to sensitize human 
tumors to standard chemotherapy, since combination of VSV and Doxorubicin 
treatment led to higher extent of apoptotic areas and areas with cytopathic effects 
within tumor sections compared to VSV or Doxorubicin treatment alone. Thus, 
results obtained in vivo underpin in vitro data (figure 16). VSV spreading appeared 
not to be impaired in vivo (figure 18A) indicating that increased apoptosis 
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originates from the combined effect of VSV and Doxorubicin treatment and not 
from improved viral spreading. 
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7. Discussion 
 
Oncolytic viruses represent a novel class of anti-cancer agents. Development of 
replication-competent viruses addresses the limited capacity of standard therapies 
to cure solid human cancers. Therapeutic success of oncolytic agents finally will 
depend on a thorough understanding of both the biology of the therapeutic virus 
and its interaction with cancerous and non-cancerous tissue. In the thesis presented 
here, virus-host-interactions between oncolytic viruses and human cancer cell lines 
were investigated to tightly restrict oncolytic virus infection to tumor cells. In a 
first project, a novel concept was established that for the first time refers to the 
destruction of oncolytic viruses in normal cells, thus aiming to prevent generation 
of viral break-through long time after treatment. This approach involved the 
application of a highly specific DNA endonuclease from yeast (I-Sce I) that was 
expressed by the oncolytic Adenovirus in a p53-selective manner. Secondly, the 
Vesicular Stomatitis Virus (VSV) is a long studied animal virus but only for about 
35 years its meaning as anti-tumor agent is unraveled. Research is focused on wild 
type, mutant and engineered viruses. Nonetheless, the interaction of VSV and 
mammalian cells appears to be rather complex especially when considering that 
the virus only encodes five proteins and that a major part the matrix protein is 
responsible for manipulating the infected cell. Here, special emphasis was set on 
the meaning of proteins of the Bcl-2-family in VSV infected tumors. 
 
7.1 Recombinant adenoviral vectors  
 
The literature provides a wealth of concepts to restrict adenoviral replication and 
subsequent cell lyses to cancerous cells while normal tissue is spared (reviewed in 
[42]). In practice, infection of tumors with a self-replicating agent eventually will 
lead to infection of normal cells as well. Frequently, this issue has been addressed 
by development of mechanisms that prevent replication of viral therapeutics in 
non-target cells. According to the underlying strategies, four different regulation 
principles can be defined: transductional, transcriptional, translational and 
apoptosis targeting [26]. 
The modification of attachment proteins on the virus surface can be applied to 
target tumor cells exposing receptor molecules that are exclusively or at least 
preferentially expressed on tumor cells, e.g. the Her2/neu tyrosine kinase receptor 
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or the epidermal growth factor receptor (EGFR) [144;178]. This so called 
transductional targeting leads to preferential virus entry into cancer cells. This 
strategy includes the activation of viral surface proteins by proteases that are 
abundant in tumor-specific microenvironments [179] and expression of virus-
encoded soluble fusion molecules [180].  
Another concept (apoptosis targeting) involves the modification of viral genes 
whose products are essential for virus propagation in normal cells but are 
dispensable in tumor cells [37]. Deletion of adenoviral E1 genes that inhibit 
apoptosis and cell cycle arrest in infected cells renders Adenoviruses sensitive for 
p53 and RB induced apoptosis in normal cells. In contrast, in tumor cells with 
frequently occurring non-functional p53 and RB proteins E1-deleted Adenoviruses 
still are capable of generating infectious offspring without inducing cell death 
[181;182]. 
DNA viruses like Herpes Simplex Virus or Adenovirus can be transcriptionally 
restricted to tumor cells by inserting promoters that are primarily active in tumor 
tissue and regulate the transcription of genes that are essential for viral replication. 
In the case of Adenoviruses, promoters of the prostate specific antigen (PSA) 
[183] or the human telomerase reverse transcriptase (hTERT) [184] allowed a 
conditional replication in tumor cells. In recent years, development switched from 
rather simple promoter arrangements to more complex gene networks to limit virus 
replication to cancer cells. One example was introduced by our group applying a 
p53-sensor and a transcription repressor element [74]. 
It was suggested recently that genes responsible for cancer development are 
involved in anti-viral defense mechanisms as well [14;15]. A prominent example 
is the interferon system that represents a key module of innate anti-viral immunity 
and is often inactivated in tumor cells [36]. This difference between normal and 
cancerous cells for example can be exploited by the naturally tumor-selective virus 
Vesicular Stomatitis Virus (translational targeting). Normal VSV-infected cells 
initiate a strong IFN response leading to a global shut down of translation in 
neighboring cells. In contrast, cancer cells with impaired IFN signaling pathways 
remain susceptible to VSV infection since biosynthesis of VSV proteins is not 
inhibited. Based on this concept VSV vectors were created that show an increased 
specificity for cells with impaired IFN-pathways. In a first study, mutation of a 
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viral key protein (VSV-M) restored interferon release [94] while in another 
approach an IFN-β gene was inserted into the virus genome [147]. 
However, these regulatory circuits are observed to be overcome by physiological 
circumstances finally allowing the emergence of viral particles from normal tissue 
(“leakiness”) [185;186]. This was attributed to several mechanisms such as “auto-
activation” feedback loops of regulated viral genes and limited attenuation of the 
applied tissue-specific promoters that control viral genes essential for replication 
[186-189]. Additionally, infection of non-target cells with high amounts of 
infectious particles will allow for undesired viral replication. Thus, more 
sophisticated regulation concepts are required to increase safety profiles of 
existing oncolytic viruses. 
The concept presented here (figure 6) provides a novel approach to render 
adenoviral vectors permanently non-functional by specific destruction of the viral 
genome. Central tool to achieve vector DNA destruction is the yeast endonuclease 
I-Sce I. In contrast to other endonucleases, the rare-cutting enzyme I-Sce I displays 
promising properties for the application in this concept. It has been reported that 
expression of the enzyme is well tolerated by mammalian cells suggesting that 
these complex genomes do not or only to a very limited extent provide I-Sce I-
recognition sequences [82]. Importantly, the 18 bp long recognition sequence can 
not be found in the genomic information of human Adenovirus type 5.  
To learn about functional properties of I-Sce I, first experiments were performed 
on basis of plasmids in cell culture. It could be observed that the enzyme is 
properly localized to the cell nucleus of human cancer cells and that it does 
possess a detectable capacity to specifically cleave circular or linear target reporter 
vectors (figure 5). However, data suggest a strong reaction of human cells on I-Sce 
I-mediated cleavage as they efficiently repair DNA double strand breaks ([152], 
personal communication with F. Pagues, Cellectis SA). To enable proper 
monitoring of I-Sce I-cleavage, it appeared to be reasonable to insert more than a 
unique I-Sce I-recognition site in the viral genome. Since I-Sce I is reported to be 
more efficient when concentration of target sequences was low [190] the number 
of recognition sequences in the adenoviral backbone was limited to two I-Sce I-
sites. Furthermore, two I-Sce I-sites can be placed in inverted or directed 
orientation in an adenoviral genome because the 18 bp long recognition sequence 
is non-palindromic. In general, excision of a recognition site-framed adenoviral 
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DNA region was supposed to lead to a rapid circularization of the resulting 
fragment. This circularization would prevent a latter recruiting as a possibly 
“missing piece fragment” into other cleaved fragments to render an inactivated 
adenoviral backbone functional again. Noteworthy, fusion of DNA ends with no or 
only little sequence homology by the non-homologous endjoining (NHEJ) 
pathway leads to destruction of intact cleavage sites. Thus, adenoviral backbones 
encoding the inverted recognition site setup upon cleavage and religation would 
result in an excised, circular DNA fragment that could not be rescued by I-Sce I-
cleavage since the recognition site is destroyed during the religation step [152]. In 
contrast, the directed orientation could result in re-cleavable fragments. 
Nonetheless, these mechanisms have to be further investigated in detail. 
Since E1A has been demonstrated to be the major regulator of adenoviral 
replication it was chosen as target for transcriptional regulation in a variety of 
studies. Most prominently, heterologous promoters are utilized to restrict E1A 
expression to a desired cell type or tissue [58-62;184]. Therefore, one cleavage 
sites of I-Sce I was inserted 5’ of the E1A gene to separate the gene from its 
driving promoter upon I-Sce I cleavage (figures 6, 7). The second recognition 
sequence was situated downstream of the E1B genes. This setup allows the 
excision of the whole E1 gene family that is essential for initiation of adenoviral 
replication – and for cellular transformation. Integration of an intact E1 DNA 
region into a mammalian genome has previously been reported to be sufficient for 
transforming human embryonic kidney cells [50]. 
Upon generation, recombinant adenoviral particles were analyzed for their protein 
expression patterns to check functional integrity of the constructed genomes. 
Correct expression of regulatory proteins was a prerequisite for the functioning of 
the concept. Subsequently, the activity of virus-encoded I-Sce I protein was 
analyzed. To this end, it was hypothesized that – within a pool of very different 
cleavage-religation products – circularized E1 fragments might have emerged that 
could be detected by PCR indicating I-Sce I cleavage. As a matter of fact, expected 
PCR products were exclusively detected in p53-positive cells. In contrast, for 
EGFP-encoding viruses or in p53-impaired cells, the cleavage activity could not be 
examined. This underlines the selectivity of the p53-dependent promoter prMin-
RGC and its use in the provided concept.  
7. DISCUSSION  81 
   
After exploring certain characteristics of the regulation system, the test of the 
constructed viruses provided evidence for proof of the concept in oncolysis assays 
applying p53-positive and p53-deleted/impaired cell lines. Viruses being regulated 
by a prMin-RGC-I-Sce I-switch were more selective to p53 than their control 
vectors (factor 10 – 100) while exposing comparable lytic levels in p53-impaired 
cell lines. Surprisingly, the CMV-setup provided a higher selectivity than the 
hTERT-viruses in A549 cells. In contrast, in HepG2 cells the hTERT viruses were 
superior to CMV-viruses regarding restriction. Activation of hTERT expression is 
an essential element of cancer development in humans while this is not observed in 
normal differentiated cells [65]. Thus, integration of an hTERT promoter in an 
adenoviral setup to control E1A expression adds an additional level of selectivity 
to the replication regulation mechanism. According to this, it seems questionable 
that differences regarding hTERT status of HepG2 and A549 might explain the 
differing results. Rather, an experiment including non-transformed cells would 
yield reasonable results on this issue. 
Similar results were observed as well when I-Sce I-switch and an additional 
transcriptional regulation by Gal4-KRAB were combined. For these viruses (Ad-
CMV- or Ad-hTERT-Gal4-KRAB-I-Sce I) gain of selectivity showed comparable 
values (factor 10 – 100) when compared to the corresponding EGFP-controls. As 
viruses harboring both regulation principles showed an almost similar lytic pattern 
in cells with impaired p53 status, it can be concluded that combining these 
regulators renders the viruses more selective. This is in concordance with former 
reports about combining two separate regulatory elements [61;66]. 
The first and very prominent oncolytic adenoviral vector, Addl1520 (Onyx-015), 
was tested as control vector. Originally, replication of ONYX-015 was reported to 
be exclusively dependent on the p53 status of an infected cell. This assumption 
was based on deletion of the E1B-55k gene that is known to inactivate functional 
p53 protein. While ONYX-015 replicated normally in p53-dys-functional cells it 
did not propagate in p53-positive cell lines. However, following reports questioned 
the role of p53 on selectivity of ONYX-015. Rather, differential late viral mRNA 
export seems to be determining selectivity of Onyx-015 [72]. Independently of 
these discussions, ONYX-015 has maintained its meaning as important standard 
vector since it is currently subject of clinical trials. Compared to ONYX-015 all I-
Sce I-encoding viruses exhibited a higher restriction in p53-positive cells, thus 
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demonstrating functionality of the I-Sce I-concept. Importantly, I-Sce I-encoding 
viruses performed equally or even better in cells with deleted or mutated p53 genes 
(figure 10). 
Taken together, the application of a genome-destruction switch that acts p53-
selectively and specifically on adenoviral DNA provides a new tool for restricting 
viral replication to cancer cells. Nonetheless, based on the provided data questions 
arise that will have to be answered to demonstrate an advantage over previously 
described regulative mechanisms. First, results for selectivity have to be verified in 
other additional lines to provide evidence for a generalized application. Performing 
experiments in isogenic cell lines only differing in the transcriptional status of p53 
[191] would greatly enhance validity of the so far obtained data. Next, it can be 
speculated whether excision of a genomic region that is essential for viral 
replication results in decreased levels of mRNA and protein of E1A since cleavage 
separates the driving promoter from the E1A gene. It can be assumed that there is 
a competition between prMin-RGC-promoter and the promoter controlling E1A. If 
transcription of the E1A gene is initiated rapidly and leads to high amounts of 
functional protein, I-Sce I-cleavage will not result in block of adenoviral 
replication. This can be observed for high applied MOIs in oncolysis assays (figure 
10, MOIs = 5 – 20, A549, HepG2). Importantly, these examinations should be 
performed within the early phase after infection. 
As alternative to this “transcriptional explanation”, in a replication-based theory it 
could be argued that decreased numbers of adenoviral genome templates (lacking 
the essential left ITR) are responsible for the observed effects. Analysis of the 
number of genomic DNA templates in p53-positive and –negative cell lines would 
address this question.  
Thirdly, the concept claims to inactivate viruses in normal cells. Generation of free 
DNA-ends by destruction of adenoviral DNA activates DNA repair pathways that 
could activate cell death programs [152]. Thus, survival of infected normal cells 
has to be tested to exclude apoptosis-targeting as underlying regulation 
mechanism.  
If all these questions are answered, a fourth point seems worth to be explored: 
cleavage products of adenoviral DNA might be subjected to error-prone repair and 
can be incorporated into the cells genome. Integration of the E1 region should be 
prevented as the combination of these genes possesses transformative potential 
7. DISCUSSION  83 
   
[50]. It has been previously shown that I-Sce I-mediated excision of an EGFP gene 
from a plasmid vector leads to integration into Xenopus genomes [192]. This 
indicates that integration of DNA fragments is not only a theoretical challenge. 
Additionally, this observation supports the strategy to limit the number of I-Sce I-
recognition site to minimize the amount of cleavage products. In order to prevent 
insertion of functional adenoviral genes into the host genome, an alternative 
positioning of the I-Sce I-cleavage sites – such as within the E1A gene – might 
pose a solution.  
In addition to the potential transformative potential of the generated cleavage 
products, there occurs another problem based on the action of DNA repair 
processes. Cleavage and subsequent religation of adenoviral cleavage products 
might result in functional adenoviral backbones that were rendered I-Sce I-
insensitive by destruction of one or both inserted cleavage sites. To limit the 
emergence of these I-Sce I-insensitive break-through mutants, it might be 
promising to insert additional I-Sce I-sites in the adenoviral backbone. 
Alternatively, and in conjunction with the aim to reduce the transformative 
potential of this concept, altered positioning of cleavage sites within the E1A gene 
would be a smart solution. Since DNA repair processes were demonstrated to be 
highly error-prone (deletions and insertions of nucleotides were reported) [152], 
this would inactivate the E1A gene e. g. by frame-shift-mutations.  
Noteworthy, this concept requires novel virus production processes. Usually, 
adenoviral vectors are propagated in 293 cells. These cells are stably transfected 
with an intact adenoviral E1 region that leads to degradation of p53. However, 
monitoring virus infection clearly demonstrates residual p53 function since prMin-
RGC promoter allowed expression of EGFP in control viruses. Thus, it has to be 
assumed that I-Sce I is expressed as well. This certainly increases the risk of 
amplification of I-Sce I-insensitive mutant particles that impair safety of the 
vector. However, preliminary experiments with p53-deficient H1299 and Hep3B 
cells resulted in unsatisfying viral titers thus requiring different cell lines. 
 
In summary, it can be concluded that the application of the yeast meganuclease I-
Sce I represents a promising strategy to degrade conditionally replicating 
Adenoviruses in p53-selective manner. The provided results demonstrated a high 
selectivity and efficacy profile of the constructed vectors that is superior to other 
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established regulation mechanisms. Future efforts will be made to promote the 
established concept by providing valid data on the mechanism of action.  
 
 
 
7.2 VSV-mediated Mcl-1 destruction 
 
The natural tumor virus Vesicular Stomatitis Virus (VSV) is known to selectively 
infect and destroy human cancer cells while normal cells are spared from cell lysis. 
Great effort has been made to investigate underlying mechanisms for tumor 
selectivity. Several studies have demonstrated a strong dependence of VSV on an 
impaired interferon system [34;93]. Other cellular components like the tumor 
suppressor protein p53 have also been reported to play a role in handling VSV 
infection in mammalian cells [14;116]. Importantly, oncolytic viruses destroy 
infected cells subsequent to infection. In this process induced apoptosis seems to 
play a more or less important role for the replication cycle of different 
therapeutically exploited viruses. Usually, induction of apoptosis limits viral 
amplification, and therefore viruses have developed different strategies to prevent 
premature apoptotic cell death prior to the completion of the viral life cycle 
[193;194]. On the other hand, virus-induced apoptosis can not simply be 
interpreted as anti-viral defense mechanism. Rather, it was described that 
apoptosis might facilitate release of viral offspring from infected cells to enhance 
viral spreading [195;196]. For VSV the process and meaning of induced apoptosis 
have been investigated in several studies. VSV was reported to trigger apoptosis at 
early stages in the viral life cycle [125]. Shortly after infection and uncoating of 
virions but prior to synthesis of viral proteins and start of replication, apoptosis is 
induced. Surprisingly, even UV-inactivated viruses were capable to induce 
apoptotic cell death. This observation is not unique for VSV but is in concordance 
with results obtained for other viruses like Sinbis virus [197], reovirus [198] and 
vaccinia virus [199]. For VSV, a crucial role for the viral matrix protein was 
suggested in inducing apoptosis since transfection of mRNA of the viral M-protein 
is sufficient to elicit apoptosis in human neural cells in the absence of other viral 
components [126;127]. In the same study, for BHK cells the contribution of 
another unknown viral component that contributes to induction of apoptosis has 
been proposed [127]. On the molecular level it has been described that VSV 
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infection leads to activation of caspase-3 and caspase-3-like proteases 
[124;126;127]. For murine fibroblasts an Apaf1-mediated activation of caspase-9 
was observed [200]. Following VSV infection, caspase-9 is activated in simian 
kidney fibroblast Vero-76 cells [169], HeLa and BHK cells [201]. While for wild 
type VSV caspase-8 activation has been challenged [169], certain mutant VSV 
strains exclusively induce apoptosis via the extrinsic pathway employing caspase-8 
[139]. In the here presented study, caspase-3 activation was measured to evaluate 
induction of apoptosis. For the analyzed human cancer cell lines HepG2, A549 and 
Huh-7 caspase-3 activity markedly increased 24 hours post infection at MOI = 0.1. 
In concordance, for Vero-76 cells an increase of caspase-3 activity has been 
reported 2 – 3 hours post infection, though cells were infected with much higher 
amounts of virus (MOI = 50) [169]. 
In HeLa cells caspase-8 and -9 activities were reported to be reduced by over-
expression of the anti-apoptotic Bcl-2 protein [202]. Furthermore, over-expression 
of Bcl-2 was shown to inhibit downstream effects of VSV-mediated activation of 
caspase-3 such as PARP-cleavage and DNA fragmentation [124]. Additionally, the 
cellular level of Bcl-xL declines in VSV infected Vero-76 cells [169]. These 
results demonstrate an important role for members of the Bcl-2 family of proteins 
in virus-host-interaction. In order to investigate the impact of VSV on this protein 
family, human cancer lines were infected with low MOIs of wild type VSV and 
subsequently analyzed for levels of proteins associated to apoptotic pathways. In 
line with earlier results Bcl-2 and Bax protein levels were not altered following 
VSV infection, whereas the decline for Bcl-xL was not reproducible in these 
experiments [124;169]. Surprisingly, one member of the Bcl-2 family of proteins, 
myeloid leukemia cell 1 (Mcl-1) protein, showed a marked decrease of protein 
levels when cells are infected with wild type VSV (figure 11A). This decrease was 
not demonstrated to be dependent of the p53 status of the infected cells. 
Additionally, this decrease is independent of caspase cleavage since general 
inhibition of caspase activity by the pan-caspase inhibitor z-VAD-fmk was unable 
to stabilize Mcl-1 protein levels. In contrast, application of MG132 resulted in 
significant recovery of Mcl-1 protein levels suggesting a role of the proteasome 
system in Mcl-1 degradation. This is consistent with former results where E1A- or 
DNA-damage-mediated Mcl-1 destruction could be blocked by application of 
MG132 or the structurally different proteasome inhibitor epoxomicin [167;203]. 
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Block of general protein biosynthesis by the transcription inhibitor Actinomycin D 
led to a drop of cellular Mcl-1 levels that displayed a noticeable similarity to VSV-
mediated Mcl-1 elimination (figure 11C). Furthermore, in a very recent report it 
was demonstrated, that the VSV mutant AV1 – that lacks the capacity to 
efficiently block host cell protein biosynthesis due to a mutation in the viral M-
protein – did not influence Mcl-1 levels what is in striking contrast to the wild type 
virus [129]. Preliminary experiments with HepG2 cells (figure 11D) confirm that 
AV1 does not influence Mcl-1 protein levels like wt-VSV.  
 
 
Figure 19. Influence of wt-VSV on host cellular protein biosynthesis. Uninfected cells 
(left side) perform protein biosynthesis by transcribing genes into mRNA, subsequent 
ripening, export and translation of these mRNAs in the cytoplasm of the cell. After protein 
folding and post-translational modifications proteins are turned over in a specific manner. 
Infection of cells with wt-VSV (right side) is followed by a rapid block of certain steps (so 
far reported for transcription, translation, and especially mRNA-export) of the host cellular 
protein production machinery to inhibit actions of anti-viral pathways. This results in lack of 
new functional host (but not viral) proteins and leads to a detectable decline of short-lived 
host cell proteins. 
 
 
In summary, these data provide evidence that VSV infection leads to a rapid 
decline of Mcl-1 protein based on the combination of blocked de novo protein 
synthesis by VSV and continuous proteasomal degradation of Mcl-1 (figure 19). It 
has been demonstrated that a Mcl-1 mutant that can not be ubiquitinated is 
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significantly more stable following VSV infection (figure 14A). This indicates that 
proteasomal degradation is mediated by the Mcl-1 ubiquitin-E3-ligase 
MULE/LASU1 [162]. However, the results described here do not exclude the 
possibility that VSV directly targets Mcl-1 for proteasomal destruction. 
Furthermore, it could not be evaluated whether GSK-3β is involved in targeting 
Mcl-1 for ubiquitination. Although it can not be ruled out, a contribution of GSK-
3β appears rather unlikely as this enzyme today is primarily known to play 
important roles in energy metabolism, cell development and body pattern 
formation [204]. The recently demonstrated link between GSK-3β and the intrinsic 
apoptotic pathway [164] might hold promise for further investigations including a 
possible role of GSK-3β in fighting viral infections via Mcl-1 phosphorylation.  
The Mcl-1 protein, among Bcl-2, Bcl-xL, Bcl-w and A1 is a member of the pro-
survival subgroup of the Bcl-2 family of proteins, although differing in certain 
structural and functional characteristics from the other proteins. Mcl-1 is situated 
in the outer mitochondrial membrane and inhibits release of cytochrome c 
[158;166]. Pro-apoptotic Bim, Bid, Puma and Noxa proteins are known binding 
partners of Mcl-1 [203;205-209]. The interaction of pro-apoptotic Bak protein and 
Mcl-1 suggests a scenario where sequestration of the Bak protein by Mcl-1 
prevents oligomerization of the pore-forming Bak molecules. However, 
mechanisms by which Mcl-1 blocks the onset of apoptosis are not yet fully 
understood and are still under constant debate.  
In contrast to other Bcl-2-family members, Mcl-1 is an early-response gene that 
can be rapidly induced and turned over [166;210;211]. This property makes Mcl-1 
an ideal early-response element in the apoptotic signaling cascades, thus playing a 
protective role against DNA damage, adenoviral infection, growth factor 
withdrawal, and treatment of cytotoxic agents [167;203;212-217]. Disappearance 
of Mcl-1 has been reported to contribute to the onset of apoptosis and is provoked 
by combining blockade of protein synthesis and continued protein degradation 
[167;203]. Consistently, when cells over-expressing wild type or a stabilized 
mutant of Mcl-1 were infected with VSV levels of apoptosis induction dropped 
markedly (figure 14B). This inhibition of apoptosis coincides with elevated levels 
of viral progeny that is produced within the first 36 hours after infection (figure 
14C). Comparable results for virus titers were reported for Jurkat cells over-
expressing Bcl-2 [124]. According to the data mentioned, it might be speculated 
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whether Mcl-1 is a general anti-viral switch that facilitates induction of apoptosis 
in RNA and DNA virus-infected cells. Based on its short half-life, Mcl-1 is ideal 
for sensing viral hijacking of the translation machinery. Involvement in anti-viral 
defense is further supported since Mcl-1 has been reported to be down-regulated 
by other viruses (Adenoviruses, infectious pancreatic necrosis virus) as well 
[203;218].  
While the role of Mcl-1 in the apoptotic pathways is getting clearer much less is 
known about its involvement in autophagy. Autophagy is an ancient cellular 
degradation process for proteins, organelles and cytoplasm, that promotes both cell 
death and survival and participates in innate and adaptive anti-viral immune 
responses [219]. Recently, a weak interaction between Mcl-1 and Beclin-1, a Bcl-2 
interacting protein that promotes autophagy has been reported [220]. Since VSV 
was observed (figure 13) and reported to induce autophagy [171;172] it was 
interesting to investigate a possible contribution of Mcl-1 to autophagy. The over-
expression of a stabilized Mcl-1 mutant in VSV-infected cells did not significantly 
alter the observed state of autophagy compared to infected parental cells indicating 
that Mcl-1 neither directly nor indirectly is involved in autophagy in VSV-infected 
cells. The contribution of autophagy to cancer and virus infection is ambivalent. 
Autophagy was reported to promote or to restrict cancerous development 
[221;222]. In virally infected cells, autophagy might provide a defense strategy of 
the infected cell or, in contrast, a viral mechanism to gain access to cellular 
resources [223;224]. Experiments carried out here can more or less suggest an 
exclusion of a decisive role for Mcl-1 in VSV-induced autophagy.  
In a variety of human hematopoietic and lymphoid cancers, including B-cell 
lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, mantle cell 
lymphoma and multiple myeloma, Mcl-1 has been shown to be over-expressed 
[225-230] suggesting a role in cancer development for Mcl-1. Additionally, cells 
with elevated Mcl-1 levels exhibit a more resistant phenotype to conventional 
chemotherapeutic treatment than cells with normal Mcl-1 protein levels [173;174]. 
Thus, several strategies to target Mcl-1 have been described including small 
molecule inhibitors [209;231-234], anti-sense molecules and RNA interference 
[235;236]. In this work it was shown that VSV leads to Mcl-1 clearance from 
infected cells. Therefore, the possibility was investigated that these infected cells 
are rendered more susceptible to apoptotic stimuli in particular conventional 
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chemotherapy (Doxorubicin). As a result, combined VSV-virochemotherapy 
induced apoptosis to a higher extent than VSV or Doxorubicin treatment alone. 
This result could be observed in vitro and in vivo (xeno-transplanted nude mice). 
Based on the results of different apoptosis assays (caspase-3 activation, TUNEL), 
it can be concluded that the enhanced anti-tumor effect of combined 
virochemotherapy depends on higher levels of apoptotic cell death. In concordance 
with former reports applying different Mcl-1 inhibition strategies [209;230-236], 
this is caused by VSV-mediated sensitization of cancer cells to Doxorubicin 
treatment.  
Several viruses such as alpha and gamma herpesviruses or adenoviruses are known 
to express homologues of Bcl-2 family members to prevent premature cell death 
by inhibiting release of cytochrome c from mitochondria [237;238]. A well 
illustrating example appears to be Adenoviruses that harbors E1B-19k [239]. E1B-
19k takes over anti-apoptotic function from Mcl-1 (binding Bax and Bak) that is 
degraded in consequence of adenoviral E1A expression [203]. It has been reported 
that VSV produces higher levels of progeny when Bcl-2 protein is stabilized [124]. 
Additionally, in the here presented work Mcl-1 was shown to be a cellular factor 
that is degraded following VSV infection. Stabilization of Mcl-1 led to increased 
VSV titers like demonstrated for Bcl-2 stabilization. Based on the mentioned data, 
the question might be raised why VSV did not acquire the ability to express a Bcl-
2 homologue during evolution as observed in other viruses? VSV infects a wide 
range of organisms thus lacking a clear host specificity. Expressing an additional 
gene product like a Bcl-2-homologue on one hand might improve virus 
amplification to a limited extent. Concomitantly, this might be accompanied by 
loosing fitness as a longer genome probably will demand more resources (time, 
energy) to replicate thus reverting the before mentioned positive effect. 
Importantly, in contrast to Adenoviruses, expression of Bcl-2 or Mcl-1 did not 
completely abrogate apoptosis while viral replication proceeded. While the 
adenoviral replication cycle takes about 48 hours, VSV amplifies in less than 24 
hours. Therefore, inhibition of apoptosis might be irrelevant for VSV. Taken 
together with the fact that induction of apoptotic cell death is not required for VSV 
replication [124], additional suppression of apoptosis by Bcl-2 homologues simply 
might not tremendously improve viral amplification rates.  
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This study is the first to describe a physiologically important relationship between 
VSV and Mcl-1 in apoptosis with implications for cancer therapy demonstrating 
that Mcl-1 can be down-regulated by VSV infection in a proteasome dependent 
manner. Furthermore, as the VSV-mediated Mcl-1 decrease can be exploited 
therapeutically, this study represents a potential advancement in the understanding 
of oncolytic VSV therapy of human cancers. Though several findings point to 
protein biosynthesis shut-down to be responsible, further direct signaling to Mcl-1 
can not be excluded, and could represent an interesting issue for further studies. 
 
7.3 Outlook 
 
The present work focused on investigations on the interactions of oncolytic viruses 
with human cancer cell lines. The data provided here demonstrate that application 
of highly specific DNA endonucleases represents a powerful tool to control 
replication and perhaps maintenance of oncolytic DNA viruses. Furthermore, 
cleavage of viral backbones not only allows for selective destruction of oncolytic 
viruses in normal cells but prevents a later break-through of underlying replication 
control mechanisms. To test this hypothesis further research on stress response 
pathways and an involvement of apoptosis in the established concept is necessary. 
The natural tumor virus VSV initiates the destruction of the anti-apoptotic Bcl-2 
family member Mcl-1 in human cancer cell lines rapidly after infection. Data 
indicate that the Mcl-1 protein is a key component of the cell’s defence against 
VSV infection. Additionally, the obtained data provide strong evidence that this 
anti-viral mechanism can be successfully exploited to enhance anti-tumor therapy 
in combination with conventional chemotherapy in vitro and in vivo.  
Independently of the here presented work, it has to be noted that oncolytic 
virotherapy – the underlying concept of this thesis – can only be one component of 
a mosaic of amultimodal therapeutic strategies that might finally achieve to cure 
cancer. In recent years, simple reliance on oncolytic vectors has been replaced by 
concepts activating the patient’s innate and adaptive immunity against neoplastic 
lesions by the help of viruses. Thus, pure virotherapeutic approaches might end up 
as part of a bigger picture, though, having paved the road for novel therapeutics to 
treat solid human cancers. 
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9.2 Abbreviations 
 
Ad Adenovirus 
APS ammonium persulfate 
ARF another reading frame 
ATP adenosine triphosphate 
ATCC Amercian Tissue Culture Company 
ATP adenosine triphosphate 
AV1 attenuated virus 1 (mutant VSV) 
β-gal β-galactosidase 
Bcl-2 B-cell lymphoma 2 
bp base pairs 
BSA Bovine serum albumin 
CMV Cytomegalovirus 
CO2 carbon dioxide 
CPE cytopathic effect 
CQ chloroquine 
DAPI  4',6-diamidino-2-phenylindole dihydrochloride 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxyribonucleotides (dATP, dGTP, dCTP, dTTP) 
DTT dithiothreitol 
E.coli Escherichia coli 
E1A Adenovirus early region 1A 
E1B Adenovirus early region 1B 
EDTA ethylenediaminetetraacetic acid 
eIF2α eukaryotic initiation factor 2 alpha 
EGFP enhanced green fluorescent protein 
EtOH ethanol 
FCS fetal calf serum 
fw forward 
g acceleration of gravity 
h hour 
H2O  water 
HCC hepatocellular carcinoma 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP horseradish peroxidase 
hTERT human telomerase reverse transcriptase 
i.t. intratumoral 
i.v.  intravenous 
I-Sce I intron-encoded meganuclease from the Saccharomyces cerevisiae 
IL interleukin 
IRES internal ribosomal entry sequence 
kDa  kilodalton 
KRAB Krüppel associated box 
lacZ β-galactosidase 
LB Luria Broth 
LC3 microtubule-associated protein 1 light chain 3 
luc luciferase 
M molar 
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Mcl-1 myeloid cell leukemia 1  
MCS multiple cloning site 
mg  milligram 
MHH Hannover Medical School 
min  minute 
ml  millilitre 
mM millimolar 
µg  microgram 
µl microlitre 
µm  micrometre 
µM  micromolar 
MOI multiplicity of infection (= viral particles per cell) 
NSCLC  non-small cell lung cancer 
OD optical density 
ONPG ortho-nitrophenyl-β-galactoside 
ONYX-015 conditionally replicating Adenovirus of ONYX Pharmaceuticals, Inc. 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pfu plaque forming unit 
prMin-RGC p53-dependent promoter 
rev reverse 
RNA ribonucleic acid 
RNase ribonuclease A 
RNAi RNA interference 
rpm rounds per minute 
RT room temperature 
S.D. standard deviation 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamid gel electrophoresis 
shRNA short-hairpin RNA 
TAE Tris/acetate/EDTA buffer 
TBS  tris-buffered saline 
TBST  tris-buffered saline plus Tween20 
TE Tris/EDTA buffer 
TEMED N,N,N',N'-Tetramethylethylenediamine 
Tris 2-Amino-2,2-hydroxymethylpropan-1,3-diol 
TUNEL deoxynucleotidyl transferase (TdT)- mediated dUTP nick end labeling 
UTR untranslated region 
VSV wild type Vesicular Stomatitis Virus 
VSV-G glycoprotein of the Vesicular Stomatitis Virus 
VSV-L Vesicular Stomatitis Virus polymerase 
VSV-M matrix protein of the Vesicular Stomatitis Virus 
VSV-N nucleocapsid protein of the Vesicular Stomatitis Virus 
VSV-P phosphoprotein of the Vesicular Stomatitis Virus 
v/v volume per volume 
w/v weight per volume 
w/o without 
wt  wild type 
YFP yellow fluorescent protein 
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